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ABSTRACT 
Midbrain dopaminergic (mDA) development is a complex yet highly controlled mechanistic 
process that is conserved across species. The understanding of these molecular details can open 
windows to new avenues of therapeutic medicine. Parkinson’s disease (PD) is a debilitating 
neurological disorder that to date has no cure or established cause. With various aspects of 
mDA development being revealed, the aim for a permanent treatment of PD itself is getting 
closer. Included within this thesis are four papers and two manuscripts covering diverse points 
of mDA neuron development and PD. 
In Paper I we explore the role of transcription factor Pbx1 to promote mDA differentiation 
through activation of Pitx3 and repression of Onecut2. Pbx1 is also involved in protection from 
oxidative stress through Nfe2l1, an important aspect of PD. 
In Paper II we explore the cellular diversity of the ventral midbrain through the use of single-
cell RNA-sequencing. The cellular transcriptional profiles aid in revealing the mDA neuron 
lineage and a cross-species comparison of mouse and human. To conclude, we use molecular 
tools to evaluate stem-cell derived mDA preparations for cell replacement therapy (CRT) in 
PD. 
In Paper III we review the current knowledge of Wnt signaling related to mDA development 
and further investigate the human single-cell data set from Paper II for other possible Wnt 
components that have yet to be explored for their role in development. 
In Paper IV we explore the composition of the mDA cellular environment using RNA-
sequencing data. Here we apply a novel approach to gain insight to specific contributions from 
various cell types to the extracellular matrix, its modulators, and signaling ligands. We find a 
transcription factor network centered around Arntl1 in radial glia type 1 cells, a putative 
progenitor to the neuronal lineage. 
In Paper V we investigate the matricellular protein R-spondin 2. As a Wnt signaling activator, 
we show R-spondin 2 has a role in mDA differentiation when applied to embryonic stem cell 
differentiation protocols. This has direct translational impact in CRT for PD. 
In Paper VI we explore the role of Wnt/planar cell polarity signaling in midbrain development. 
Specifically, we elucidate the roles of Ror2 and Vangl2 in mDA development and their 
participation in morphogenesis and neurogenesis.  
In conclusion, this thesis encompasses research on midbrain development from molecular 
details at a single-cell level to cellular components affecting global developmental processes. 
Here I present findings to be included towards a greater understanding of midbrain 
development and novel ideas relevant to translational research in CRT for PD.  
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1 INTRODUCTION 
1.1 THE SHAKING PALSY 
“Involuntary tremulous motion, with lessened muscular 
power, in parts not in action and even when supported; 
with a propensity to bend the trunk forwards, and to pass 
from a walking to a running pace: the senses and 
intellects being uninjured.” 
-James Parkinson, 1817 
Exactly 200 years ago, a general practitioner described, through his observations, six individual 
cases with similar symptoms and defined them as shaking palsy. James Parkinson published 
these observations in the London Medical and Physical Journal under the title An Essay on the 
Shaking Palsy and pioneered research into this disease as a unique malady to be distinguished 
from others. Many of his observations still hold true today and importantly, allowed for 
subsequent clinicians to supplement onto his findings. Although his proposed means of a 
remedy today would be considered erroneous, including induced skin blistering and 
bloodletting from the neck in order to reduce blood pressure to the brain, he carefully states 
how his observations should be considered and how to move forward. 
“The inquiries made in the preceding pages yield, it is to be 
much regretted, but little more than evidence of inference: 
nothing direct and satisfactory has been obtained.” 
With his humility, and following the scientific method, we continue to question, observe, and 
analyze and build upon what those before us have discovered.  
Even though he did not have a cure, he expressed hope of a treatment to stop the progress of 
the disease and advocated early intervention for success. Today, 200 years later, we continue 
to work in the realm of text written by James Parkinson in his essay about the shaking palsy. 
“…there appears to be sufficient reason for hoping that some 
remedial process may long ere discovered, by which, at least, 
the progress of the disease may be stopped.” 
1.1.1 History 
It was not until 50 years after James Parkinson when Jean-Martin Charcot made more detailed 
observations and the term Parkinson’s disease (PD) was first used. Charcot made a clear 
distinction in the symptoms, specifically between rigidity, weakness and bradykinesia. Today, 
by definition, the disease is manifested in the classical symptoms: resting tremor, rigidity, 
bradykinesia, and postural instability (Fahn, 2003). Starting in the early 1900’s, more 
discoveries were made into the pathology of PD including observations made by Frederic Lewy 
in 1912, 100 years after Parkinson’s initial observations. He described the discovery of 
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microscopic particles within cells of diseased patients which later were found to be mostly 
composed of α-synuclein and be termed Lewy body inclusions (Shults, 2006; Spillantini et al., 
1998), a hallmark of PD. Later on, observations by Konstantin Tretiakoff and Rolf Hassler 
would confirm that the substantia nigra pars compacta (SNc) was the main cerebral structure 
affected. In the 1950s, a breakthrough in dopamine research came that would eventually earn 
Arvid Carlsson, along with Paul Greengard and Eric R. Kandel, the Nobel Prize in Physiology 
or Medicine in 2000. Arvid Carlsson discovered that dopamine was a neurotransmitter found 
in the basal ganglia region of the brain and that treating animals with reserpine caused PD like 
symptoms which could be reversed with the administration of L-DOPA (levodopa), a precursor 
in the dopamine synthesis process. Further research then translated to the first human trial with 
use of L-DOPA as a therapy under the research of Oleh Hornykiewicz in 1961. By 1967, L-
DOPA was commonly used as a treatment for the movement symptoms of PD and is still being 
used today. Since the 1960’s many discoveries surrounding the molecular processes of PD have 
been made due to the advancement in technology, methodologies, and overall understanding 
of the disease. The discovery by Spillantini, Trojanowski, Goedert (1997) that α-synuclein is 
the main component of Lewy bodies added significant understanding to the pathology of the 
disease (History of PD reviewed in Goetz, 2011). 
As the culmination of research over the past decades continued, the true test would come with 
the introduction of cell transplants in human patients in the late 1980s and early 1990s. Today, 
these early trials are still considered as the proof of concept for a future stem cell-based cell 
replacement therapy (CRT) for PD that is now around the corner. 
1.1.2 Current knowledge on PD 
Today, PD affects about 2% of the world’s population over the age of 65 and is the second 
most common neurodegenerative disorder after Alzheimer’s disease. PD occurrence is highly 
correlated with age, but in some cases though, patients acquire early-onset forms of the disease 
(before 50 years of age) (de Lau and Breteler, 2006). Clinically, the loss of midbrain 
dopaminergic (mDA) neurons in the SNc results in the manifestation of the classical motor 
symptoms of the disease.  
Although it is these symptoms that we associate with PD, many other cell types are affected 
such as noradrenergic neurons in the locus coeruleus (Hassler, 1938), peptidergic neurons 
(Agid et al., 1986), or serotonergic neurons (Chaudhuri et al., 2006) are responsible for non-
motor symptoms. Some of the cell types impaired also give insight into how the disease 
progresses over time. One convincing idea, the Braak theory and staging system proposes the 
start of the disease in the lower part of the brainstem, the medulla oblongata as well as the 
olfactory bulb, where early Lewy bodies can be detected and then progresses upward in the 
brainstem and affects parts of the autonomic, limbic, and somatomotor systems (Braak et al., 
2003, 2007). Furthermore, theories on origin of PD within the gut are also convincing, affecting 
cells of the enteric nervous system, consistent with early symptoms such as constipation, and 
then spreading of α-synuclein to the central nervous system (Klingelhoefer and Reichmann, 
2015). Beyond these early affected regions, late stage PD symptoms in the form of cognitive 
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decline give indication to the spreading of the disease to the cortical regions of the brain 
(Schapira et al., 2017; Wolters and Francot, 1998). 
Despite the extensive knowledge about the various pathological features of PD, the cause of 
the disease is still a mystery with some research reporting ties to environmental factors, and in 
less than 10% of cases some genetic links even though they are not fully penetrant. Some of 
these genetic hallmarks include mutations in genes such as α-synuclein (SNCA), leucine-rich 
repeat kinase 2 (LRRK2), GBA, PARK2, PINK1, and VPS35 (Bonifati, 2014; Trinh and Farrer, 
2013) among others. Dominantly inherited and late-onset forms of PD include missense 
mutations in SNCA, LRRK2, and VPS35. Recessively inherited missense mutations found in 
early onset forms of PD include the RBR E3 ubiquitin protein ligase, parkin (PARK2), the 
PTEN induced putative kinase 1 (PINK1), the protein deglycase DJ-1 (PARK7), and the 
ATPase type 13A2 (ATP13A2). Furthermore, a large-scale genome-wide association study has 
identified additional risk loci associated to PD (Nalls et al., 2014). 
Mutations in these genes affect various molecular pathways leading to abnormal cellular 
processes that could lead to pathogenesis of PD. Many of these genes affect intracellular protein 
aggregation, protein trafficking and lysosomal-autophagy activity. The first major implicated 
gene in PD was α-synuclein. Under normal conditions, α-synuclein associates with synaptic 
vesicles and is broken down through lysosomes or proteasomal degradation. Under 
pathological conditions, α-synuclein accumulates and forms fibrils that are not degraded and 
disrupt processes such as intracellular trafficking, endosome-lysosome function and contribute 
to oxidative stress and mitochondrial dysfunction. α-synuclein can also be transmitted from 
one neuron to the next in a prion like manner, giving rise to a pathological spreading of disease. 
Some of the other genes mentioned above are also known to play various roles in these 
pathways and are thought to interact (for extensive review, see Abeliovich and Gitler, 2016). 
90% of the cases of PD are currently thought to be idiopathic, that is without known cause. As 
in many other diseases, environmental factors such as diet, toxic substances and infectious 
agents have been suggested. However, evidence for a causative role has only been well 
documented in few patients exposed to the DA neurotoxin MPP+ (Langston et al., 1983). PD 
thus appears to be a multifactorial disorder where no single contributing factor is currently 
known or can explain the majority of the cases. At the same time, there is a certain degree of 
individual variation between PD patients with regard to onset, progression, clinical 
manifestations and response to treatment. 
1.1.3 Current treatments 
Without a clear understanding of origin of disease, current treatments do not address the 
underlying cause of disease and focus on symptomatic relief. In most cases, treatment of these 
patients involves administration of different types of drugs and in some cases more invasive 
surgical interventions.  
Traditionally, replacing the loss of the neurotransmitter, dopamine, and its function has been 
the main target of pharmacological intervention. Today, the most common and the gold-
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standard for the treatment of PD is L-DOPA, the precursor of dopamine and other 
catecholamines. L-DOPA, can be administered orally and is currently combined with 
carbidopa to prevent its metabolism and increase the proportion of L-DOPA that passes the 
blood-brain barrier. Once it has entered the central nervous system, it can be converted into 
dopamine by aromatic L-amino acidic decarboxylase (AADC; Dopa decarboxylase, DDC) and 
in turn increase available dopamine needed for neurotransmission. Long term use of L-DOPA 
results in decreased efficacy and adverse effects such as motor fluctuations and dyskinesias 
(Cenci, 2007; Huot, 2015; Whitfield et al., 2014). 
Another pharmacological treatment consists of the use of synthetic dopamine receptor agonists 
to stimulate the target neurons expressing dopamine receptors and regulate neural activity. Two 
of the more common medications are pramipexole and ropinirole. Although less potent than L-
DOPA, dopamine receptor agonists can result in side-effects that vary patient to patient, such 
as hypersexuality and gambling behaviors, emphasizing the importance of case based 
recommended treatment. 
Targeting dopamine degrading enzymes with inhibitors in order to supplement or maintain 
neurotransmitter production and reduce recycling is another method of medication. This 
includes MAO-B inhibitors to block an enzyme in the brain that catabolizes L-DOPA. COMT 
(catechol-O-methyl transferase) inhibitors can also be used, to affect the metabolism of L-
DOPA and extending its biological half-life. Many other medications exist that help to alleviate 
specific symptoms of PD and can be prescribed based on patient circumstances. 
Surgical treatments offer a different spectrum of treatments but are more invasive and reserved 
for more severe conditions. The most common surgical treatment is the implantation of 
electrodes in the subthalamic nucleus for deep brain stimulation. Deep brain stimulation has 
been approved as a PD treatment since 1997 and similar to the various prescribed medications, 
patient selection is key for positive outcome (Krack et al., 2017; Miocinovic et al., 2013). 
Nevertheless, none of these treatments are a true cure as they do not change the progressive 
course of the disease and patients often require higher doses or increased stimulation over time. 
To this end, other methods need to be considered. 
1.1.4 Cell replacement therapy 
CRT has been developed over several years as a candidate alternative to dopamine 
neurotransmitter replacement therapy. Although several different cell types have been used for 
cell transplantation, it has become clear that mDA cells are required for efficient cell 
replacement. The first transplant study using human fetal ventral midbrain (VM) tissue was 
performed in Lund, Sweden, in 1989. This and subsequent trials demonstrated that CRT was 
possible, but that the cell preparations and transplantation had to fulfill certain criteria 
(reviewed in Lindvall and Kokaia, 2009). These pioneering clinical trials provided proof of 
concept for CRT. However, while some patients from these trials have shown positive benefits 
well over 15 years post-transplant (Kefalopoulou et al., 2014), others have shown little, none, 
or in some cases worsening of symptoms. To investigate further into possible explanations for 
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this, one more clinical trial is currently being conducted with fetal VM tissue to confirm the 
importance of variables such as cell preparation, transplantation, patient selection, 
immunosuppression and outcome measures for CRT (TRANSEURO) (Kirkeby et al., 2017a). 
Nevertheless, we should remember that even though CRT can show long-term positive results, 
it still only aims at alleviating the motor symptoms of PD and it is now well understood that 
PD, as it progresses, affects more than just movement, and can give non-motor symptoms 
including depression, dementia, sleep disturbances, and gastro-intestinal complications, some 
of which arise even before the motor symptoms (Kalia and Lang, 2015; Park and Stacy, 2009; 
Schapira et al., 2017).  
Although fetal tissue has been successfully used for CRT, this is not a viable solution for the 
treatment of PD in the future. The use of fetal tissue raises ethical issues that needs to be 
carefully taken into consideration. Fetal tissue is also not practical due to its limited access and 
the need of tissue pieces from several fetuses (up to 3-4) in order to get enough cells to treat 
just one brain hemisphere of a PD patient. This type of therapy also introduces a problem of 
standardization, as each cell preparation derives from various different donors and tissues are 
not in the same condition. For CRT to become a standardized method that could be 
implemented in a reproducible manner to multiple patients, it is essential to have an accessible 
and up-scalable cell source, standardize all the procedures and consistently obtain high quality 
cell preparations. It is currently thought that human pluripotent stem cells (hPSCs) are the most 
optimal starting population for CRT (Barker et al., 2015). hPSCs can be obtained from 
blastocysts (embryonic stem (ES) cells), or by reprogramming of somatic cells, such as skin 
fibroblasts, the so called induced pluripotent stem (iPS) cells. hPSCs have shown the capacity 
to differentiate into mDA neurons and provide functional recovery in animal models of PD 
(reviewed in Sundberg and Isacson, 2014).  
A third novel strategy for CRT is the replacement of DA cells by transformation of existing 
non-neuronal cells in the brain. It has been shown that direct in vivo transformation of 
astrocytes to mDA neurons is possible by using viral vectors in a mouse model of PD (Rivetti 
di Val Cervo et al., 2017). These strategies for PD CRT are outlined in Figure 1.  
hPSCs of various sources are currently used in clinical trials to treat a wide range of disorders 
including PD (Trounson and McDonald, 2015). hPSCs have the capacity to expand and to 
differentiate into all cell types of the body, therefore, treatment of PD and other disorders 
appears to favor this methodology. Although the general idea of the correct cell type required 
for CRT in PD is agreed upon (mDA neurons), there are many different protocols and the quest 
to produce bona fide SNc DA neurons (Arenas et al., 2015) is still ongoing. In addition, it is at 
present unclear what constitutes or defines a perfect human DA cell type for transplantation? 
and whether or not the cells produced in vitro resemble sufficiently their in vivo counterparts? 
and how much should they resemble with regard to gene expression and function to be 
considered as suitable for transplantation? To answer these questions, we need to: (1) gain a 
better definition of mDA neuron development in vivo and what is the composition of their 
environment, the VM; (2) Apply developmental knowledge to improve stem cell differentiation 
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protocols; (3) Establish molecular-functional correlates before and after transplantation with 
the goal to improve efficiency and safety of mDA cell preparations; and (4) Develop standard 
protocols to obtain cell preparations with reproducible quality and safety.  
 
Figure 1: Cell replacement therapy strategies 
Schematic of CRT approaches for PD. Different approaches include use of human fetal tissue for transplantation 
either directly or after expansion. hPSCs such as ES (derived from blastocysts) or iPS cell lines (derived from 
fibroblasts) could be differentiated into DA cells and used for transplantation. Fibroblasts could also be directly 
converted to mDA cells in vitro and then transplanted. Alternatively, somatic cells in the adult brain, such as 
astrocytes, could be reprogrammed in vivo into mDA neurons. NES: neuroepithelial stem cell; DP: dopaminergic 
progenitor; DNb: dopaminergic neuroblast; DAn: dopaminergic neuron. 
As the scientific community in the field addresses and answers more of these questions, we are 
getting closer to the implementation of CRT for PD patients. Optimization and standardization 
of clinically safe cells for CRT is a whole endeavor in itself due to strict permissions and 
regulations on how to conduct these trials. Furthermore, making conclusions based on mouse 
pre-clinical data and translating that to human has shown to be difficult in several different 
clinical trials only to result in no efficacy for humans. This is in part related to the fact that the 
animal models do not capture all aspects of human disease, but also to the fact that many of the 
fundamental aspects of development applied to human stem cells come from studies in rodents 
and may differ from developmental processes in human, misguiding thus our efforts. One 
example of this are the species differences in Wnt/β-catenin signaling between mice and 
human; while Wnt/β-catenin activation was not required in mouse ES cell cultures for mDA 
differentiation, it has proven to be essential for the specification of hPSCs into midbrain floor 
plate and their correct differentiation into mDA neurons (Kirkeby et al., 2012; Kriks et al., 
2011; Xi et al., 2012). More emphasis thus needs to be placed on comparative studies and in 
translating human developmental mechanisms to protocols to improve current stem cell 
preparations and make them suitable for human therapy. It is therefore essential that we gain a 
better understanding, in the case of PD, of the factors critical for VM development. Using 
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today’s technologies to gain insight of in vivo developmental processes in human, such as 
single-cell RNA-sequencing (scRNA-seq) and CRISPR/Cas9 technologies, we are 
approaching a level of understanding of gene expression and function in human development, 
that is allowing us to improve the way we capture and recapitulate this process in a dish. We 
think this knowledge will translate in improved hPSC-derived mDA neuron preparations for 
CRT in PD.  
One important aspect for translational research, in addition of cell intrinsic factors, such as 
transcription factors, and cell extrinsic factors, such as morphogens and growth factors, is the 
extracellular matrix (ECM). The physiological role of ECM components has been largely 
ignored in most differentiation protocols. The implementation of new ECM components, as 
well as new methodology to culture and differentiate stem cells in 3D environments may be 
important to replicate in vivo conditions and to improve CRT for PD in the future. Simple 
scaffold matrixes or manipulation of adhesion surface for cells to differentiate and migrate have 
shown to significantly impact cell maturation and survival (Ni et al., 2013; Wang et al., 2016; 
Zhang et al., 2017). 
 
1.2 VENTRAL MIDBRAIN DEVELOPMENT 
For the last few decades, numerous factors involved in midbrain development have been 
thoroughly studied (for comprehensive review see Arenas et al., 2015; Blaess and Ang, 2015; 
Bodea and Blaess, 2015). The following sections to come briefly describe the sequential steps 
taking place during VM and mDA neuron development: Specification, Proliferation, 
Neurogenesis, Differentiation, and Migration (Figure 2). The development of the neural tissue 
begins when the ectoderm gives rise to the neural plate at embryonic day (E) 7.5 in mouse, day 
18 in human, followed by the formation of the neural folds and then the neural tube, which 
starts being formed by neurulation at E8 in mouse, day 20 in human, and is completely closed 
by E10.5 in mouse, day 29 in human (Figure 2A). The closing of the neural tube is a highly 
regulated process requiring Wnt/planar cell polarity (PCP), Shh (sonic hedgehog), and BMP 
(bone morphogenic protein) signaling. These signaling pathways and transcription factors such 
as Zic2, Pax3, Cdx2 and Grhl2/3 are in place to coordinate cell dynamics, including convergent 
extension (CE) movements, apical constriction and interkinetic nuclear migration required for 
proper neural tube formation (Figure 2A) (Nikolopoulou et al., 2017). 
1.2.1 Specification 
The neural tube is patterned by different types of secreted factors called morphogens that 
establish gradients in both the anterior-posterior and ventral-dorsal axis providing cells with 
regional identity. Two signaling centers are important for VM development: the floor plate, in 
the ventral neural tube, and the isthmic organizer (IsO), at the midbrain-hindbrain boundary 
(MHB). These structures provide the initial signals to define the VM. Extrinsic morphogens in 
early VM development include Shh, derived from the floor plate, and Wnt1 (wingless-type 
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MMTV integration site family, member 1) as well as Fgf8 (fibroblast growth factor 8), derived 
from the midbrain and hindbrain side of the IsO, respectively (Figure 2B).  
  
 
Figure 2: Ventral midbrain dopaminergic development 
A) Formation of the neural tube at E8.5 in mouse starting from the neural plate (blue) and through CE movements, 
neural folds (green) join to form cord with SHH secreting notochord (red) positioned ventrally. B) Sagittal section 
of early morphogen established boundaries that set up the VM region with gradients of SHH and WNT1. C) 
Coronal section of mouse brain at E12.5 showing postmitotic cells of the mDA lineage. Three layers and 
developmental stages can be distinguished. Proliferating progenitors are found within the ventricular zone (VZ). 
Post-mitotic mDA neuroblasts (NR4A2+/TH-, red) are present in the intermediate zone (IZ). Differentiated mDA 
neurons become TH+ (green) within the marginal zone (MZ). D) Schematic representation of the organization and 
steps during mDA neuron development. 
The floor plate arises by the action of SHH, secreted initially by the notochord ventrally, 
induces the expression of Foxa2 (forkhead box A2) in the ventral aspect of the neural tube, 
which defines the floor plate and in turn expresses Shh and initiates a SHH gradient that patterns 
the ventral-dorsal axis. More laterally, SHH regulates the expression of Nkx6-1 and Nkx2-2, 
markers defining the basal plate (Prakash et al., 2009). On the other hand, the MHB is 
established by intrinsic signals, the transcription factors Otx2 (orthodenticle homolog 2) and 
Gbx2 (gastrulation brain homeobox 2). FGF8 secreted at the IsO allows for a gradient to form 
in the anterior-posterior axis and induces Wnt1 at the anterior side of the MHB. At the same 
time, Otx2 expression regulates the expression of Lmx1a and Lmx1b (LIM homeobox 
transcription factor 1 alpha/beta), which together with Wnt1/-catenin form a critical auto-
regulatory network that controls mDA neuron development (Chung et al., 2009). Loss of any 
of these three genes has drastic consequences for the proper development of mDA neurons 
(Andersson et al., 2006; Prakash et al., 2006; Smidt et al., 2000; Yan et al., 2011).  
The midbrain floor plate thus emerges under the unique influence of two morphogens, SHH 
and WNT1, and the transcription factor networks they control. Indeed, FOXA1/2, together 
with, LMX1A and LMX1B serve important functions in specification and differentiation of 
mDA neurons (Andersson et al., 2006; Ferri et al., 2007; Smidt et al., 2000), which originate 
  9 
from progenitor cells in the ventricular zone (VZ) of the VM. These progenitors in addition to 
the transcription factors above, express Corin (Ono et al., 2007) as well as the redial glia marker 
Glast/Slc1a3 (solute carrier family 1 (glial high affinity glutamate transporter), member 3) 
(Bonilla et al., 2008). 
All these components are nowadays used to examine the quality of the differentiation of hPSCs 
into mDA neurons in vitro. Moreover, hPSCs are specified into midbrain floor plate cells by 
using SHH and activating Wnt/β-catenin signaling with FGF8 and/or GSK3 inhibitors early 
in the protocols. 
1.2.2 Neurogenesis 
Upon floorplate specification, mDA progenitors undergo neurogenesis, the process of by which 
cells divide to generate postmitotic daughter cells, which express key transcription factors such 
as the nuclear receptor Nr4a2 (nuclear receptor subfamily 4 group A member 2, also known as 
Nurr1). Initial neurogenesis is controlled by the expression of proneural basic-helix-loop-helix 
genes, such as Ascl1 (achaete-schute family bHLH transcription factor 1, also known as Mash1) 
and Neurog2 (neurogenin 2, also known as Ngn2) (Kele et al., 2006), as well as the Ferd3l 
(Fer3-like (Drosophila)), which inhibits the proneural gene suppressor Hes1 (hairy and 
enhancer of split 1 (Drosophila)) (Ono et al., 2010). These genes are influenced by the already 
established networks such as Shh-Foxa2 and Lmx1a/b-Wnt1, as well as Wnt5a, which also 
controls differentiation and cooperates with Wnt1 in mDA neurogenesis (Andersson et al., 
2013; Castelo-Branco et al., 2003). 
As a consequence of all these processes, the midbrain floor plate becomes a layered structure, 
with progenitors in the VZ, the layer of cells most proximal to the mesencephalic ventricle. As 
these cells undergo neurogenesis, postmitotic cells initially migrate in a radial fashion along 
radial glia, through the intermediate zone (IZ) and to the outer most layer, the marginal zone 
(MZ), where mDA neurons emerge (Figure 2C-2D). DA neurogenesis takes place between 
E10 and E14.5 in mouse and between 6 to 11 weeks post conception in humans (Almqvist et 
al., 1996; Nelander et al., 2009). 
1.2.3 Differentiation 
Commonly, mDA neurons are defined as such when they express the rate limiting enzyme for 
dopamine synthesis, Th (tyrosine hydroxylase), although maturation through electrical 
signaling properties and functional circuit integration come later. From neurogenesis, the cells 
subsequently differentiate into mature mDA neurons in the MZ (Figure 2C-2D). This process 
continues to build upon previous network of genes and is supported by additional players. Some 
transcription factors such as Nr4a2, En1 (engrailed 1), and Pitx3 (paired-like homeodomain 
transcription factor 3) have regulatory roles and control other genes such as neurotrophic 
factors and genes essential for proper functional integration and dopamine release. Trophic 
factors include Bdnf (brain-derived neurotrophic factor), Gdnf (glial cell line derived 
neurotrophic factor) and its receptor, the c-Ret proto oncogene. Other genes involved in 
neurotransmitter identity and function include Slc18a2/Vmat2 (solute carrier family-18 
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member-2/vesicular monoamine transporter-2), Slc6a3/Dat (solute carrier family-6 member-
3/dopamine transporter), Drd2 (dopamine receptor D2), Ddc, and Aldh1a1 (aldehyde 
dehydrogenase family 1, subfamily A1), all of which are part of the machinery essential for the 
production, release, and recycling of dopamine (reviewed in (Arenas et al., 2015; Hegarty et 
al., 2013; Rekaik et al., 2015)). 
1.2.4 Migration 
At around E14.5, no further progenitors are contributing to the mDA neuron pool. During 
neurogenesis, cells migrate in a radial fashion through the IZ to the MZ, in part due to 
chemokine signaling involving Cxcr4/Cxcl12 (chemokine (C-X-C motif) receptor 4 / 
chemokine (C-X-C motif) ligand 12) as well as the ECM protein Reln (reelin) (Bodea et al., 
2014; Yang et al., 2013b). From this point, mDA neurons migrate in a tangential direction until 
they reach their final positions where they will integrate into local circuitry postnatally, 
contributing to roles including, control of motor behavior, reward, decision making and 
learning. Several types of mDA neurons have been identified based on their anatomical 
position and where they project their axons. Briefly, these include the SNc DA neurons, which 
mainly project to the dorsal striatum, the VTA (ventral tegmental area) DA neurons that project 
to the prefrontal cortex and the limbic system, and the RRF (retrorubral field) DA neurons that 
project to the dorsal striatum, limbic system and prefrontal cortex (Bodea and Blaess, 2015; 
Roeper, 2013). 
 
1.3 DOPAMINERGIC NEURONS 
Understanding the different subtypes of mDA neurons in the VM is important not only from a 
developmental perspective, but also from a disease perspective, as SNc DA neurons are the 
most vulnerable to PD and their demise leads to the clinical manifestations that characterizes 
this disease (Damier et al., 1999; Javoy-Agid and Agid, 1980; McRitchie et al., 1996). 
The developing VM is known to give rise to these three similar but spatially separated mDA 
neuron populations, the SNc, VTA, and RRF (Björklund and Dunnett, 2007). These distinct 
anatomically-defined mDA neurons have been more recently re-assessed and defined at a 
molecular level by examining the subsets of genes they express (Chung et al., 2005; Greene et 
al., 2005; Grimm et al., 2004). This type of work has led to the identification of markers such 
as Slc6a3/Dat and Kcnj6 (potassium inwardly-rectifying channel, subfamily J, member 6, also 
known as Girk2), which mark the SNc and dorsolateral VTA, and Calb1 (calbindin 1), 
expressed in the VTA and partially in the dorsal tier of the SNc (Fu et al., 2012; Thompson et 
al., 2005). More recently, Sox6 (SRY (sex determining region Y)-box 6) has been shown to 
localize to a subset of SNc neurons and Nolz1 (Zfp503, zinc finger protein 503) and Otx2 mark 
subpopulations of VTA (Panman et al., 2014). These are only a few genes that have been 
explored but ongoing evaluation reveals new candidates for possible separation of the mDA 
neuron population, including studies on some cells being able to co-release GABA and 
classification of cells based upon expression of different voltage gated channels (Smits et al., 
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2006, 2013; Tecuapetla et al., 2010). Other interesting studies have focused on birth dating 
neurons and tracing them to adulthood, which have shown that separate populations are born 
at different time points (Bayer et al., 1995; Bye et al., 2012). 
The question is how do we define a cell type? If one would focus on just the neuronal diversity 
within the body, the list of criteria for classification causes inherent problems (Bota and 
Swanson, 2007; Fishell and Heintz, 2013; Nelson et al., 2016). Further classification of mDA 
cell types beyond the three anatomical types can be done using distinct parameters which are 
very likely to give further subdivisions and even different results (Clevers et al., 2017). For 
instance, defining a cell type based on anatomical features such as efferent projections vs. 
electrophysiological profiles will each give two sets of unique populations and up to 13 
different subpopulations (Fu et al., 2012; Roeper, 2013). Thus, defining a subtype is dependent 
on the tools used to examine them and the interpretation of the results. One solution thus is to 
use a single level of information to exhaustively examine the cells and define their identity. For 
instance, the developmental programs required to acquire discrete mDA population identities 
has not yet been fully elucidated, in part due to the dynamic/continuous nature of the process 
(for review see Bodea and Blaess, 2015) and in part due to our incomplete knowledge of the 
genes and pathways involved. Although the definition of a cell type will be discussed for many 
years to come, new advanced technologies are aiding to cluster cells based on similar features, 
as no two cells will ever be identical. 
1.3.1 Single-cell RNA-sequencing and defining cell types 
Multicellular organisms have evolved by generating specialized cells that perform specific 
roles contributing to the overall function of the organism as a whole (Arendt, 2008). In the late 
1800’s when Santiago Ramón y Cajal illustrated the cell heterogeneity of the brain based solely 
on morphology, studies that would earn him the Nobel Prize in Physiology and Medicine 1906, 
cells were classified by morphology alone. Increasing levels of information in recent years 
makes it unavoidable to think how should we define a neuron today and at what point should 
we stop making distinctions between two cells (Bock, 2013). Whether classification occurs via 
morphology, as Ramón y Cajal did, or by connectivity and electrophysiological properties, it 
is no doubt that the complexity in the specialization and connectivity of neurons requires further 
investigation. This will aid in understanding what occurs under normal physiological function 
and how pathologies arise when a certain cell type malfunctions (Luo et al., 2008; Masland, 
2004). Indeed, by being able to distinguish two similar cell types within the cellular diversity 
of an organism or tissue it could be possible to formulate new hypothesis, such as which cells 
can be targeted by specific diseases, should we know a disease mechanism; or the opposite, 
knowing cell types affected by disease, what may be the possible mechanisms. 
Classical studies using transgenic mice and biochemical methods have been for many decades 
the tool of choice to study particular cells expressing specific genes. However, the recent 
development of advanced technologies have allowed to study developmental processes, with 
high scrutiny, at a global level, and are revolutionizing the way we study mechanisms of 
development (Poulin et al., 2016). A combination of three steps: single-cell capture methods, 
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nucleic acid amplification methods, and next-generation sequencing, provided proof of 
principle and allowed a very rapid development of scRNA-seq into a robust high-throughput 
method. This method has allowed for the generation of large data sets and gaining molecular 
insights into mechanisms of development and cell type definition (Linnarsson and Teichmann, 
2016; Shapiro et al., 2013; Trapnell, 2015). The analysis of continuous process such as 
development, by capturing gene expression in cells at any given time point is like taking 
landscape pictures in time. With many pictures, a reconstruction of cell lineages can be 
obtained, contributing to understand the sequence of the underlying processes at a molecular 
level.  
From a tissue piece to single cells and sequencing, a unique genetic fingerprint of the activity 
of individual cells can be taken (Islam et al., 2011, 2012). Not only does this method allow to 
identify individual cell types by their molecular signature, but it allows to count absolute RNA 
molecules and determine the transcriptional activation of individual genes (Islam et al., 2014; 
Kivioja et al., 2011). Applying this technology to the developing VM, or any other tissue, 
allows the discovery of unknown molecular players in development as well as novel cell types 
(Marques et al., 2016; Pollen et al., 2014; Treutlein et al., 2014; Zeisel et al., 2015). Moreover, 
gene expression levels can be used not only to examine the functional state of the cell, but also 
their identity. 
A number of methods have been used to isolate single cells including manual picking, laser 
capture, FACS (Fluorescence-activated cell sorting), microfluidic devices, and microdroplets. 
Whichever method is used for single-cell isolation and capture, the following step require 
reverse transcription and nucleic acid amplification, which have just recently been modified to 
cover the genome for scRNA-seq (methods reviewed in Grün and van Oudenaarden, 2015; 
Kolodziejczyk et al., 2015). The method used in Paper II, STRT RNA-Seq, is a 5’-end 
amplification of cDNA method that allows for reduced technical variability and the 
incorporation of unique molecular identifiers for counting mRNA molecule and reducing 
amplification bias (Islam et al., 2012, 2014). Other methods allow for full-length coverage 
mRNAs (SMART-Seq) and others are 3’-end focused (CEL-Seq, Drop-Seq) (for methods 
review see Grün and van Oudenaarden, 2015; Kolodziejczyk et al., 2015). For every single-
cell experiment, it is important to consider what the goal is and expected outcome. Whether the 
goal is to investigate a very heterogeneous tissue or a FACS sorted tissue to pre-select a specific 
cell type, it is important to consider both the number of cells to be sequenced and the 
sequencing depth (number of transcripts sequenced per cell). Sampling more cells or deeper 
sequencing will result in better resolution between clustered cell types but will eventually reach 
a point where no more information is gained. Ideally, one should sequence as many cells as 
possible to achieve the highest resolution, although this has not always been feasible because 
of the early, very high cost of such experiments. This is becoming less of a problem as the 
efficiency of these methods have improved and the cost has decreased. 
The probability of finding exactly the same transcriptomic profiles in two cells using scRNA-
seq methods is very low due to transcriptional dynamics, but grouping cells based on their 
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transcriptome similarity allows for the identification of similar cell types. Different clustering 
methods have their advantages and disadvantages (Bacher and Kendziorski, 2016; Stegle et al., 
2015). In Paper II, BackSPIN is used for discovery and classification of cell types into groups 
(Zeisel et al., 2015). The high dimensionality of the data obtained from such methods has 
required very sophisticated bioinformatical tools in order to reduce this dimensionality into 
something comprehensible. The overall idea is to be able to group cells by reducing their 
dimensionality or the number of genes needed to distinguish cell type clusters. This is done by 
selecting genes that have high variance compared to that of the inherent technical noise. One 
such technique for visualizing this is t-distributed stochastic neighbor embedding (t-SNE) (Van 
der Maaten et al., 2008). Further clustering methods aid in the visualization of separation of 
groups and subgroups.  
1.3.2 RNA-Sequencing and midbrain heterogeneity 
More recently, Poulin et al., used a multiplexed single-cell qRT-PCR (quantitative real-time 
PCR) approach to resolve the heterogeneity of mDA neurons at postnatal day (P) 4 where five 
molecularly distinct mature mouse mDA neuron populations were identified based on a 
predetermined selection of genes (Poulin et al., 2014). However, a systematic and unbiased 
molecular definition of mDA neurons was not available and our knowledge of mouse, but 
particularly of human mDA neuron development was quite limited. As discussed in previous 
sections, elucidating how mDA cells diversify during development is of the outmost 
importance to be able to guide the generation of mDA neurons for PD CRT. Indeed, this 
information is very important as it may allow us to recapitulate mDA neuron development in 
vitro and make SNc DA neurons for PD CRT. Unbiased scRNA-seq currently offers the 
opportunity to interrogate the entire transcriptome of individual mDA neurons and determine 
their gene expression profiles in a systematic manner, allowing thus to reveal differences 
between cell types and transcriptional states. In Paper II (La Manno et al., 2016), we follow 
this approach to answer these questions. 
Another recent study has used FACS sorted cells from Lmx1a-EGFP mice in order to delineate 
early mDA fates (Kee et al., 2017). Using a scRNA-seq approach, the authors were able to 
differentiate between two lineages, one being the mDA lineage and the other being that of 
closely related subthalamic nucleus neurons. This data has allowed to identify contaminating 
cell types in ES cell preparations containing mDA neurons and to improve mDA differentiation 
protocols for CRT in PD (Kirkeby et al., 2017b). 
More recently, a single-cell resolution experiment has compared DA neurons from different 
regions of Th-EGFP mice at E15.5 and P7 (Hook et al., 2017). This study compared several 
DA populations in the brain in order to find specific traits of mDA cells. Although their 
resolution is lower than that in Paper II (identified only two mDA populations at E15.5), they 
did capture four populations at P7, including a SNc, a VTA, and surprisingly a postnatal 
progenitor population. They also took advantage of GWAS (genome-wide association study) 
data to identify the cell types expressing genes possibly involved in PD susceptibility.  
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1.4 WNT SIGNALING 
As mentioned above, Wnt regulates multiple aspects of mDA neuron development by 
activating different Wnt signaling pathways (for full review see Arenas, 2014). Wnts are a 
family of secreted lipid-modified glycoproteins that consist of 19 different family members in 
mammals that function as morphogens. They bind to a family of G protein-coupled seven 
transmembrane receptors, Frizzled (Fzd), and several co-receptors (van Amerongen and Nusse, 
2009). Wnt signaling plays a role in nearly all cells and tissues, where it controls multiple 
processes during embryogenesis, development, adulthood and disease. The functional diversity 
of this pathway is thought to be conveyed by the presence of multiple signaling components 
that are brought together to signaling complexes by different co-receptors (Willert and Nusse, 
2012).  
Structurally, Wnts are palmitoylated and this is fundamental for its secretion and interaction 
with receptors. Due to their high hydrophobicity, it has been difficult to crystallize and study 
the structure of Wnts. The crystal structure was finally resolved for Xenopus WNT8 connected 
to the extracellular cysteine-rich domain (CRD) of FZD8 and was shown to be in the shape of 
a ‘hand’ with the ‘thumb’ and ‘index’ finger creating the binding site to the Fzd receptor (Janda 
et al., 2012). The Fzd receptor has a hydrophobic pocket to mediate interaction with WNT and 
essential for protecting the lipid group on Wnt for crystal structure determination. The Wnt 
protein is divided into an N-terminal D1 domain and a C-terminal D2 domain with various 
hairpins and lipid-modification sites for binding. The structure has contributed to further 
understanding Wnt function and importantly, has implications for the design of new ways to 
target the signaling pathway and for drug discovery. However, the structural activation of the 
pathway, the Wnt-Fzd specificity, and the way Wnts interact with their co-receptors, still 
remains a mystery (Ke et al., 2013). 
1.4.1 History and background 
The history of Wnts is relatively recent compared to other pathways. Just over 30 years ago, 
the gene Int1 was originally identified as an oncogene as it was found to contribute to mammary 
carcinomas upon insertional activation by the Mouse Mammary Tumor Virus or MMTV 
(Nusse and Varmus, 1982, 2012). The genes of the Drosophila wingless (Wg) (Baker, 1987; 
Cabrera et al., 1987; Rijsewijk et al., 1987) and mouse Int1 were later found to be homologous 
and by combining their two names, the word/gene ‘Wnt1’ came out (Nusse and Varmus, 1992; 
Nusse et al., 1991). Over subsequent years, other Wnt family members and their downstream 
signaling components, including the receptor Fzd (Bhanot et al., 1996) and the co-receptor 
Lrp5/6 (low-density lipoprotein receptor related protein 5/6) were discovered (Pinson et al., 
2000; Tamai et al., 2000; Wehrli et al., 2000). 
Secretion of Wnts is performed with the aid of Porcupine (Porcn) in the endoplasmic reticulum 
and Wntless (Wls) within the Golgi network. Porcn is a palmitoyl transferase for lipid 
modification on the Wnt protein, which is necessary for binding to Fzd receptor, and Porcn 
loss leads to retention of WNT within the cell. Wls, is required for transport of WNT to the 
  15 
plasma membrane and secretion. Beyond secretion, extracellular transport of Wnt is not clear 
as evidence suggests different mechanisms such as protein carriers, exosomes or secretory 
vesicles. Although Wnt secretion and transport appear simple, evidence is conflicting and 
seems to be cell context-dependent (Takada et al., 2017).  
Wnt signaling has been classically divided into two main pathways. One being the β-catenin 
dependent signaling pathway, also referred to as the canonical pathway, and the other being β-
catenin independent, referred to as the non-canonical pathways. Briefly, In the OFF state, a 
destruction complex leads to the phosphorylation and proteasomal degradation of β-catenin. In 
the ON state, activation of the WNT/β-catenin-dependent pathway by the ligand leads to a 
stabilization of β-catenin in the cytoplasm, which translocates to the nucleus and regulates gene 
transcription. There are two main WNT/β-catenin-independent pathways, the Wnt/PCP 
pathway, which induces cytoskeletal changes, and the Wnt/Calcium (Ca2+) pathway, which 
induces calcium fluxes and is important for cell homeostasis (De, 2011). A schematic of the 
different Wnt signaling states and pathways is shown in Figure 3 The presence and regulation 
of diverse Wnt signaling components, ligands, receptors and co-receptors, within a cell 
determines how the WNT signal is transduced. WNTs can thus signal in many different ways 
depending on the cell types, their position (exposure to different ligands and modulators) and 
time (varying signaling components). For reviews on the complexity of Wnt signaling, see for 
instance Komiya and Habas (2008) and Niehrs (2012). 
1.4.2 Wnt/β-catenin signaling 
In the OFF state, when Wnt is not present or signaling is being inhibited, the destruction 
complex residing in the cytoplasm binds to and phosphorylates β-catenin, marking it for 
degradation by the proteasome. The destruction complex consists of the scaffold protein AXIN 
(Axin1/2) interacting with β-catenin, adenomatosis polyposis coli (Apc), beta-transducin repeat 
containing E3 ubiquitin protein ligase (Btrc), and the serine-threonine kinases glycogen 
synthase kinase 3α/β (Gsk3α/β) and casein kinase 1 α/δ (Ck1α/δ). GSK3 and CK1 
phosphorylate β-catenin which then allows the E3 ubiquitin ligase, β-TrCP, to ubiquitinate β-
catenin, marking it for proteasomal degradation. Within the nucleus, target genes are not 
transcribed and transcription factors interacting with -catenin, T cell factors (Tcf) and 
Lymphoid enhancer factor (Lef) are bound and repressed by Groucho (Figure 3, left) (Nusse 
and Clevers, 2017).  
In the ON state, Wnt/β-catenin dependent signaling is initiated by Wnts binding to one of the 
ten G protein-coupled FZD receptors and dimerization with LRP5/6 occurs (Figure 3, middle). 
The binding of Wnt occurs between its lipid moiety in WNT and to the hydrophobic pocket in 
the CRD of FZD. The internal domain of LRP5/6 is phosphorylated and the scaffold protein 
AXIN is recruited to the membrane. DVL (dishevelled) is also recruited in the complex to the 
membrane and binds to the cytoplasmic part of the FZD receptor, and through its DIX domain 
mediates the complex of FZD-DVL-AXIN-LRP5/6. The destruction complex is then recruited 
to the membrane, subsequently β-catenin dissociates and its phosphorylation is then inhibited. 
Activated (dephosphorylated) free β-catenin accumulates in the cytosol and translocates to the 
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nucleus. Once in the nucleus, it acts as a co-activator to transcription factors of the TCF/LEF 
family to promote transcription of Wnt target genes. Target genes can be cell-type specific but 
some common targets genes include C-myc, CyclinD1, and Axin2 (Nusse and Clevers, 2017). 
  
Figure 3: Wnt/β-catenin dependent and independent signaling 
Overview of different states and pathways of Wnt signaling. Left: When WNT is not present or being inhibited, 
in the OFF state, β-catenin is phosphorylated by GSK3β and CK1 in the destruction complex allowing for the 
ubiquitination of β-catenin by βTrCP and destined from proteasomal degradation. Transcription is inhibited by 
transcriptional corepressor Groucho. Middle: Activation of Wnt/β-catenin dependent signaling is triggered by 
WNT binding to FZD-LRP5/6 receptors, DVL/AXIN is recruited to membrane along with the destruction 
complex. β-catenin is then neither phosphorylated nor targeted for degradation, allowing for the stabilization and 
accumulation of in the cytosol and its subsequent translocation to the nucleus to control transcription by binding 
to TCF/LEF. Right: Activation of Wnt/β-catenin independent signaling results from WNT binding to FZD or a 
number of other receptors coupled to alternative intracellular signaling components of the Ca2+ or PCP pathway. 
Wnt signaling is highly regulated by various inhibitors and modulators. Dickkopf proteins 
(DKKs) are the best well characterized family of secreted Wnt/βcatenin signaling antagonists. 
This family is formed by 4 members (DKK1-4). While DKK1/2/4 bind to LRP5/6 to disrupt 
Wnt signaling, DKK3 does not bind LRP5/6 and it can either block or activate Wnt/βcatenin 
signaling. Another form of modulation is via the sFRPs (secreted FZD-related proteins) of 
which there are 5 members (Sfrp1-5). sFRPs contain a CRD that shows similarities to that of 
FZD, which allows them to bind to WNT directly. sFRPs can also bind to the Fzd receptor to 
prevent WNT binding. A similar mode of inhibition by binding directly to WNT can also occur 
with WIF1 (Wnt inhibitory factor-1). Due to the ability of both sFRPs and WIF1 to bind to 
WNT directly, these inhibitors can affect all the Wnt pathways. Other effectors of the Wnt 
pathway include Wise/Sost, Igfbp-4, Shisa, Waif1a, Apcdd1, and Tiki1 (For comprehensive 
review see Cruciat and Niehrs, 2012; Malinauskas and Jones, 2014). 
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1.4.3 Wnt/planar cell polarity signaling 
This pathway gets its name because it controls the polarization of cells within a plane. During 
development, the spatial and temporal distribution of cells is critical for the formation of the 
organism. WNT/PCP regulates the asymmetric distribution of proteins within the cells, the 
orientation of cilia and CE movements (cell migration and intercalation). In vertebrates, the 
process of CE is important first in anterior-posterior axis formation during gastrulation 
(Heisenberg et al., 2000; Tada and Smith, 2000)., Neurulation is also driven by CE movements 
(Ciruna et al., 2006; Tawk et al., 2007; Wallingford and Harland, 2002). Other developmental 
processes controlled by PCP signaling in mammals include, but are not limited to hair cell 
orientation (Guo et al., 2004), inner ear sensory hair cell orientation (Curtin et al., 2003; 
Montcouquiol et al., 2003), orientation of cilia (Song et al., 2010), axon guidance 
(Fenstermaker et al., 2010), and limb elongation (Gao et al., 2011). These cellular processes 
are highly conserved across species and essential for correct development and organogenesis. 
Wnt/PCP was first discovered in Drosophila mutants exhibiting alterations in cuticular 
processes (Gubb and García-Bellido, 1982). Core PCP components in Drosophila include 
frizzled, disheveled, prickle, van gogh/strabismus, flamingo, and diego. Many of these core 
components are conserved in vertebrates and have expanded to form families of signaling 
components (Wansleeben and Meijlink, 2011), such as Frizzled3/6, Dvl1/2/3, Prickle1/2 
Vangl1/2 (vang-like 1/2 (van gogh,, Drosophila)), Celsr1/2/3 and Ankrd6 (ankyrin repeat 
domain 6). Beyond the orthologs found in vertebrates and Drosophila, additional PCP related 
genes have been identified in vertebrates including Ptk7 (protein tyrosine kinase 7), Scribble 
and Ror1/2 (receptor tyrosine kinase-like orphan receptor 1/2) receptors. For comprehensive 
review on PCP signaling see (Gao, 2012; Singh and Mlodzik, 2012; Yang and Mlodzik, 2015). 
Typically, Wnt/PCP signaling is activated by Wnt5a or Wnt11 (Andre et al., 2015; Heisenberg 
et al., 2000; Yamaguchi et al., 1999) and involve the Fzd receptors Fzd3 and Fzd6 (Hua et al., 
2014; MacDonald and He, 2012). However, this pathway can engage additional co-receptors 
and alternative receptors such as ROR2, RYK (receptor-like tyrosine kinase), and PTK7 
(Figure 3, right). Upon binding of WNT to FZD and/or a co-receptor, FZD recruits DVL and 
complexes with DAAM1 (dishevelled associated activator of morphogenesis 1). 
Phosphorylation of DVL leads to downstream activation of the small GTPases RHOA and 
RAC, which leads to the activation of downstream effectors such as ROCK and JNK. This 
pathway induces modifications in actin and in the cytoskeleton, which is necessary for such 
processes as cell migration and polarity. As mentioned above, alternative receptor usage has 
also been described. One example is the Wnt5a-Ror-Dvl, which also controls morphogenesis 
(Ho et al., 2012). For review on Wnt/β-catenin-independent signaling see Sugimura and Li 
(2010), Gao (2012), and Yang and Mlodzik (2015).  
Although the signaling pathway described above seems quite linear, the PCP pathway can 
affect the Wnt/β-catenin pathway at several levels in a receptor-dependent manner (van 
Amerongen et al., 2008). For example, Ryk, considered to signal independent from β-catenin 
was shown to regulate Wnt/β-catenin signaling and control neurite outgrowth (Lu et al., 2004). 
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This can also be seen in the inhibition of Wnt/β-catenin signaling by WNT5A in a dose 
dependent manner, where WNT5A binds to the ROR2 receptor. This does not affect β-catenin 
levels but instead inhibits transcriptional activation. In the same study, it was also shown that 
in some non-neural tissues WNT5A can bind to FZD4-LRP5 and activate Wnt/β-catenin 
signaling (Mikels and Nusse, 2006). These opposing effects on Wnt/β-catenin signaling has 
also been shown in vivo (Van Amerongen et al., 2012). Many more examples exist in which 
these pathways interact and control the same functions in cooperative or opposing manners. 
Evidence over the years has uncovered an unexpected level of complexity and interaction 
between these pathways. A more integrative and cell context-dependent view of Wnt signaling 
is thus emerging. 
1.4.4 Wnt signaling and disease 
Wnt signaling has been found to play a role in many diseases such as cancer and 
neurodegenerative disorders (MacDonald et al., 2009). Mutations in Wnt related components, 
such as APC, are associated to cancer and it also makes the Wnt pathway a target for therapeutic 
approaches (Serafino et al., 2016; Zimmerman et al., 2012). For review of Wnt signaling and 
cancer see Polakis (2012).  
Within the nervous system, Wnt signaling plays important roles in maintaining proper 
homeostasis and diverse alterations have been found in neurodegenerative diseases, such as 
Alzheimer’s or PD (Berwick and Harvey, 2012; Inestrosa and Arenas, 2010; Salašová et al., 
2017; Toledo et al., 2008). In particular, Wnt dysfunction has been found to play a specific role 
in synaptic function (Purro et al., 2014). In agreement with this, blocking Wnt signaling with 
DKK1 induces synaptic disassembly and restoring Wnt reverses this effect (Galli et al., 2014; 
Marzo et al., 2016).  
 
1.5 WNTS IN DOPAMINERGIC NEURON DEVELOPMENT 
The two major Wnts during mDA neuron development are Wnt1 and Wnt5a, which activate 
the Wnt/β-catenin and Wnt/PCP pathways, respectively, but can have an effect on each other. 
While Wnt1 plays a general role in midbrain patterning, progenitor proliferation, DA 
specification and differentiation, Wnt5a has been shown to play a role in VM morphogenesis, 
decreasing DA progenitor proliferation and promoting mDA maturation (reviewed in Arenas, 
2014; Inestrosa and Arenas, 2010).  
1.5.1 Wnt1 
Wnt1 is essential for early development and specification of the floor plate in the VM and was 
one of the first genes to be targeted by knockout technology in mice (Thomas and Capecchi, 
1990). Wnt1 is one of the main activators of Wnt/-catenin signaling and is expressed early in 
the developing midbrain floor plate, in the anterior part of the MHB, and in the roof plate. At 
later stages, when the first TH+ neurons appear, Wnt1 is detected as two bands on either side of 
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midbrain floor plate (Prakash et al., 2006). Wnt1 null mice reveal a severe phenotype consisting 
on the loss of the MHB during development (McMahon and Bradley, 1990; Thomas and 
Capecchi, 1990). The midbrain shows a severe reduction in size, and few poorly mis-specified 
progenitors that give rise to severely reduced number of DA neurons that fail to mature 
(Andersson et al., 2013; Ellisor et al., 2012; Prakash et al., 2006). Other important functions of 
Wnt1 include the maintenance of En1 expression, which is required for the formation of the 
midbrain-hindbrain region (Danielian and McMahon, 1996), and of FGF8, which is required 
for maintaining Wnt1 expression (Chi et al., 2003; Prakash et al., 2006; Ye et al., 1998). 
Furthermore, conditional deletion of Wnt1 with En1Cre or ShhCre, result in a loss in specification 
as seen by the loss of LMX1A expression and reduced medial mDA neurons or reduced 
proliferation and neurogenesis, respectively (Yang et al., 2013a). Notably, Wnt1 also 
antagonizes Shh signaling in the midbrain floor plate, a step necessary for midbrain 
neurogenesis (Joksimovic et al., 2009). 
The extensive in vivo studies on the function of Wnt1 in midbrain development have had a 
profound impact on the development of in vitro protocols for the differentiation of pluripotent 
stem cells and neural progenitors into mDA neurons. Using either conditioned media or 
activation of the Wnt1 pathway with GSK3β inhibitors has allowed for the expansion and 
differentiation of VM cultures to mDA neurons (Castelo-Branco et al., 2003, 2004). Moreover, 
their subsequently implementation in hPSC differentiation protocols (Kirkeby et al., 2012; 
Kriks et al., 2011) has led to the achievement of correctly specified mDA neuron preparations 
that successfully engraft and rescue motor symptoms in animal models of PD. Together, Wnt1 
and activation of the Wnt/β-catenin pathway is critical for multiple steps of mDA neuron 
development from early specification to late survival, in mouse models in vivo and in human 
stem cells in vitro. 
1.5.2 Wnt5a 
Besides Wnt1, the other most well-studied Wnt in mDA development is Wnt5a, a Wnt that 
signals through the PCP pathway in the VM (Andersson et al., 2008). In particular, our group 
has provided evidence that Wnt5a controls morphogenesis, proliferation and differentiation of 
DA neurons (Andersson et al., 2008, 2013; Parish et al., 2008; Schulte et al., 2005). Wnt5a 
expression appears just after Wnt1 in the VZ of the VM and progressively refines to the floor 
plate and the midline, extending also to the MZ (Andersson et al., 2008). Wnt5a-/- mice show 
increased progenitor proliferation and number of post-mitotic mDA neuroblasts that fail to fully 
differentiate into mDA neurons. Wnt5a-/- mice also showed morphogenesis defects such as a 
lateral expansion of the VM domain, shortening in the anterior-posterior axis and altered 
orientation of radial glia (Andersson et al., 2008). Furthermore, in vitro studies have shown that 
WNT5A protein decreases progenitor proliferation and promotes differentiation of neuroblasts 
towards mDA neurons in both primary cultures and stem cell preparations (Andersson et al., 
2008, 2013; Bryja et al., 2007; Castelo-Branco et al., 2003; Parish et al., 2008; Schulte et al., 
2005).  
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Wnt5a has also been shown to cooperate or oppose to the function of Wnt1 in the VM. These 
types of interactions have been uncovered by the analysis of double Wnt1 and Wnt5a null mice 
embryos (Andersson et al., 2013). This work showed that Wnt/β-catenin and Wnt/PCP 
pathways not only regulate distinct processes, but they also compete or synergize during mDA 
neuron development. Compound Wnt1-/-;Wnt5a-/- mice showed a greater reduction in the 
number of post-mitotic NR4A2+;TH- neuroblasts and TH+ mDA neurons compared to single 
null mutants, as well as a greater widening and shortening of the VM suggesting a cooperation 
of both Wnts in functions previously attributed to Wnt/β-catenin, such as neurogenesis, or 
typical Wnt/PCP functions, such as elongation of the anterior-posterior axis. 
To date, the function of only a few possible WNT5A receptors have been examined in the VM, 
including Fzd3, Fzd6, Celsr3, and Ryk (Blakely et al., 2013; Fenstermaker et al., 2010; 
Stuebner et al., 2010). In vitro and in vivo analysis of these receptors have shown similar or 
stronger phenotypes compared to Wnt5a-/- mice. Indeed, Celsr3 mutant mice showed 
abnormalities in anterior-posterior guidance of DA projections (Fenstermaker et al., 2010). The 
receptor Ryk regulated mDA differentiation and axon morphogenesis in vitro, but no effects on 
axonal growth and guidance were observed in vivo (Blakely et al., 2013). On the other hand, 
Fzd3 and Fzd6 were found to be required for midbrain morphogenesis, as shown in severe 
morphogenic defects in double knockout mice, including collapsed ventricle, but also show 
delay in mDA neuron development (Stuebner et al., 2010). These results point to a certain 
degree of receptor redundancy and to the possibility of compensations taking place in vivo. 
To date, the function of other receptors such as Ror2 and PCP components such as Vangl2 in 
mediating WNT5A and Wnt/PCP signaling has not been examined in the VM. A previous 
report indicated that Ror2 and Vangl2 are required for Wnt5a signaling in limb development 
(Gao et al., 2011). In this system, a WNT5A gradient establishes PCP by inducing VANGL2 
phosphorylation through ROR2 and CK1δ. The function of Ror2 as a possible receptor for 
Wnt5a and of Vangl2 in the VM is investigated in Paper VI.  
1.5.3 Other Wnts and Wnt modulators 
Other Wnts and Wnt pathway components have been examined in VM development. For 
example Wnt2, an activator of Wnt/β-catenin pathway was found to promote mDA progenitor 
proliferation both in primary VM cultures treated with WNT2 and in and Wnt2-/- mice (Sousa 
et al., 2010). This phenotype was similar to that of the Lrp6 null mutant mice (Castelo-Branco 
et al., 2010), a co-receptor used by Wnt2. Other Wnts such as Wnt8 are important in setting up 
the MHB in zebrafish (Rhinn et al., 2005, 2009), and Wnt7a/b has been found to regulate VM 
neurogenesis and DA axon growth and guidance (Fenstermaker et al., 2010; Fernando et al., 
2014; Fougerousse et al., 2000). 
Inhibitors of the Wnt pathway also have regulatory functions in mDA development. Dkk1 
deletion lacks significant head structures anterior to the midbrain during embryogenesis and 
analysis of the few surviving Dkk1-/- and Dkk1+/- embryos revealed that Dkk1 is required for 
not only for midbrain morphogenesis, but also for mDA differentiation (Ribeiro et al., 2011). 
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Wnt modulators such as Sfrp1 and Sfrp2 are also expressed in the developing VM. Surprisingly, 
Sfrp1-/-;Sfrp2-/- embryos display a similar phenotype to that of Wnt5a-/- embryos, indicating that 
Sfrp1 and Sfrp2 are required for Wnt/PCP signaling. Indeed, while low concentrations of 
SFRP1 and SFRP2 promoted mDA differentiation, high concentrations in vitro impaired their 
survival in VM primary cultures or in mouse ES cells differentiated into mDA neurons (Kele 
et al., 2012). Thus, SFRP1 and SFRP2 seem to play a dual role to activate or inhibit Wnt/PCP 
at low and high concentrations, respectively.  
1.5.4 R-Spondins 
R-Spondins (Rspo1-4) are a family of cysteine-rich secreted proteins containing a 
thrombospondin type I repeat (Figure 4A), initially discovered in 2002 (Chen et al., 2002). It 
has long been known that RSPOs are Wnt/-catenin signaling activators (Kazanskaya et al., 
2004) and they do so through their CRD (Kim et al., 2008). In addition, RSPO3 and RSPO4 
can also have an effect on non-canonical signaling, by interacting through their 
thrombospondin domain with proteoglycans of the syndecan family (Astudillo et al., 2014; 
Ohkawara et al., 2011). In addition, RSPOs are not only considered as activators of Wnt 
signaling but rather as synergistic activators. Indeed, simultaneous exposure of cells to both 
RSPOs and WNT proteins result in a synergistic, robust activation of Wnt signaling 
(Kazanskaya et al., 2004; Kim et al., 2005). 
 
Figure 4: R-Spondin Signaling 
A) Domain structure of R-Spondin. SP: signal peptide; FU-CRD: Furin-like cysteine-rich domain; TSP: 
Thrombospondin domain; BR: Basic amino acid rich domain. B) R-Spondins enhance Wnt signaling through 
sequestering away E3 ubiquitin ligase RNF43/ZNRF3. Left: When R-Spondin is not present, RNF43/ZNRF3 bind 
to and ubiquitinate the FZD receptor. This causes internalization of receptor complex and prevent further Wnt/β-
catenin signaling from occurring. Right: In the presence of R-Spondin, RSPO binds to its receptor LGR4/5/6 and 
co-receptor RNF43/ZNRF3, thereby downregulating its activity at the membrane. This in turns allows for 
enhanced Wnt signaling. 
 22 
 
The identity of RSPO receptors has been a matter of debate in the past. Initially it was reported 
that RSPOs bind to LRP5/6 receptors as Wnts do (Li et al., 2009; Nam et al., 2006; Wei et al., 
2007), with some additional role of Fzds. Other studies (Binnerts et al., 2007) identified 
Kremen1 (Krm1), an LRP5/6 co-receptor, as a RSPO receptor. Subsequently, RSPOs were 
found to be the ligands of the leucine-rich repeat-containing G protein-coupled receptor (LGR) 
4/5/6, but not LRP5/6 (Carmon et al., 2011; Glinka et al., 2011; de Lau et al., 2011). More 
recently, two additional WNT/RSPO signaling components: The transmembrane E3 ubiquitin 
ligases ring finger protein 43 (Rnf43) and the zinc and ring finger 3 (Znrf3) were identified as 
RSPO receptors (Hao et al., 2012; Koo et al., 2012). In the absence of RSPO, ZNRF3/RNF43 
are thought to bind to the WNT/FZD complex and target the Fzd receptor for degradation by 
ubiquitination (Figure 4B, left). With RSPO present, RNF43/ZNRF3 form a complex that is 
cleared from the membrane leading to increased Wnt signaling (Figure 4B, right). Structural 
studies have shown a direct interaction of RSPOs with LGR receptors and RNF43/ZNRF3 
(Chen et al., 2013; Wang et al., 2013; Zebisch et al., 2013). It is currently thought that RSPOs 
enhance Wnt signaling by contributing to the clearing RNF43/ZNRF3 from the membrane. 
RSPO2 has been shown to play roles in morphogenesis in vivo in two different system such as 
the respiratory tract and limb development, two important areas of Wnt signaling (Bell et al., 
2008). Recently, RSPO2 was found expressed in a subset of anterior mDA neurons and its 
expression levels were found to be reduced in Lmx1a mutants (Hoekstra et al., 2013). 
Moreover, the same study showed that deletion of Rspo2 results in a modest decrease in TH 
and PITX3 levels. However, it is unknown whether loss of Rspo2 results in reduced numbers 
of mDA neurons. It has also been recently reported that a Lmx1b-miR135a2-Rspo2 regulatory 
circuit regulates Wnt signaling and the mDA progenitor pool (Anderegg et al., 2013). These 
two reports thus point to a role of RSPO2 in mDA neuron development, which so far remains 
to be fully elucidated and that we investigated in further detail in Paper V. 
1.5.5 Ror receptors 
The Ror-family of receptor tyrosine kinases are evolutionary conserved and known to 
participate in Wnt/PCP signaling. In vertebrates, this family consists of two members, Ror1/2. 
Structurally they are single pass transmembrane tyrosine kinases characterized by a kringle 
domain and a CRD domain similar to that of Fzd in the extracellular domain. The intracellular 
portion of the receptor includes a tyrosine kinase domain, two serine/threonine-rich domains, 
and a proline-rich domain (Figure 5A).  
Wnt5a signaling can cause homo-dimerization and activation of the Ror2 signaling cascade 
(Liu et al., 2008) as well as hetero-dimerization between ROR1 and ROR2 (Paganoni et al., 
2010) (Figure 5B). Signaling through Ror can be accomplished through several mechanisms 
depending on the cellular context, including other receptors and interactors of their cytoplasmic 
domains. To add to the complexity, ROR2 interacts with other Wnt receptors, including FZDs 
(Nishita et al., 2010; Randall et al., 2012). PCP signaling is usually mediated by a ROR-FZD 
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complex, but can also form complexes or directly interact with other signaling components 
such as the receptors PTK7 (Martinez et al., 2015) or RYK (Andre et al., 2012) and the secreted 
factor CTHRC1 (Yamamoto et al., 2008) (Figure 5B). Furthermore, ROR2 has been shown to 
phosphorylate and activate VANGL2 via CSNK1 (Figure 5C) (Gao et al., 2011). Other 
reported activities include antagonizing Wnt/β-catenin signaling and modulating BMP 
signaling (Stricker et al., 2017). For comprehensive review on Ror signaling, see Endo and 
Minami (2017); Petrova et al. (2014) and Stricker et al. (2017).  
 
Figure 5: Ror and Vangl signaling 
Signaling of ROR receptors and WNT5A-ROR2-VANGL2 signaling cascade. A) Schematic structure of the 
different domains of the ROR receptor. IgD: Immunoglobulin domain; CRD: cysteine rich domain; KD: kringle 
domain; TMD: transmembrane domain; TKD: tyrosine kinase domain; S/TRD1/2: serine/threonine rich domain; 
PRD: proline-rich domain. B) Possible signaling pathways and functions regulated by ROR receptor tyrosine 
kinases and other WNT receptors. Signaling is context dependent. Top: Shown to dimerize for synaptogenesis 
(Paganoni et al., 2010). Middle: In complex with FZD and/or possible other co-receptors such as PTK7, CTHRC1, 
and RYK. Part of largest signaling cascade leading to PCP pathway (Seifert and Mlodzik, 2007; Stricker et al., 
2017). Bottom: Act as a sole receptor and signal through DVL2 to maintain neural progenitor cells (Endo et al., 
2012; Ho et al., 2012). C) ROR2 can promote dose-dependent VANGL2 phosphorylation in response to a WNT5A 
gradient. This is accomplished through CKIδ. This signaling modality was found to control limb bud formation 
(Gao et al., 2011). 
In the developing nervous system, Ror family members are expressed in the VZ of the dorsal 
telencephalon, where neural progenitor cells reside. Their expression decreases during 
development up till birth. In the postnatal nervous system, Ror1 and Ror2 are absent except for 
specific cell types in the cerebellum (Al-Shawi et al., 2001; Oishi et al., 1999). It has been 
suggested that Ror1 and Ror2 have redundant functions, but that some of their effects are not 
additive (Endo et al., 2012; Paganoni et al., 2010).  
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RORs control several cellular processes such as neurite extension, cell polarization, 
synaptogenesis, cell migration, neurogenesis and cell division. Null mutation of Ror2 results 
in mice with developmental defects in heart and limb formation (Takeuchi et al., 2000). In 
humans, ROR2 mutations lead to autosomal recessive Robinow syndrome and autosomal 
dominant brachydactyly type B (Afzal and Jeffery, 2003). 
1.5.6 Vangl2 
The Vangl family members, Vangl1 and Vangl2, form a group of four-pass transmembrane 
proteins. They are known as a core PCP components for their capacity to regulate cell polarity 
and neuronal maturation (Torban et al., 2004). 
Wnts, in a dose dependent manner, induce the phosphorylation of Vangl2 through the Wnt 
receptor Ror2 (Gao et al., 2011). As seen in limb development, WNT5A gradients induce 
correlative VANGL2 activity and cell polarity (Figure 5C). On the other hand, Vangl2 
deletions in mice are more severe and result in neural tube closure defects (Gao, 2012; Kibar 
et al., 2007, 2011; Lei et al., 2010). Studies in Xenopus have also shown the interaction between 
Ror2/Vangl2 and their role in Wnt signaling (Martinez et al., 2015; Ossipova et al., 2015; 
Podleschny et al., 2015). 
 
1.6 MIDBRAIN DEVELOPMENT: NEW TRANSCRIPTION FACTORS 
As described in section 1.2, several transcription factors have been found to play key roles in 
midbrain development. Here I will focus on two additional families of genes relevant to this 
thesis. 
1.6.1 Pbx1/3 
The transcription factor family pre-B-cell leukemia homeobox (PBX) are composed of four 
members (PBX1-4) and are part of the larger TALE (three amino acid loop extension) 
homeodomain transcription factor family that includes PREP/PKNOX1/2, and MEIS1-3 
proteins (Longobardi et al., 2014). The TALE proteins structurally consist of three main 
domains, all sharing a conserved helix-loop-helix homeodomain. The two other domains are 
family specific (PBC-A/B or MEIS-A/B) conserved regions. Null mutants for several of the 
TALE family members are early embryonic lethal as these proteins play roles in early 
vertebrate brain development in cell fate specification and differentiation (Schulte and Frank, 
2014). 
Previous studies have shown that Pbx1 regulates regional identity in cortical progenitors and 
in newly generated neurons, and represses other neighboring fates (Golonzhka et al., 2015; 
Grebbin et al., 2016). Although PBX transcription factors are important in organogenesis, their 
role in midbrain development was poorly understood. Only the function of Pbx1, expressed in 
the VM, has been previously examined. Pbx1-deficient embryos show alterations in dopamine 
neuron axon guidance and in the regulation of netrin-1 receptor, Dcc (deleted in colorectal 
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carcinoma) (Sgadò et al., 2012). Other studies have identified Pbx1 as a downstream target of 
LMX1A, up-regulated in Lmx1a-deficient mice (Hoekstra et al., 2013), and downstream of 
Pitx3, downregulated in Pitx3-/- embryos (Veenvliet et al., 2013). The latter result, however, is 
in contradiction with our analysis in Paper I where we show that PBX1 is upstream of PITX3 
(Villaescusa et al., 2016). Indeed, our findings show: (1) that PBX1 protein is present in mDA 
neuroblasts and neurons, while the expression of PITX3 is only found in mDA neurons, (2) 
that Pitx3 is a direct target of PBX1 as assessed ChIP-seq analysis; and (3) that the expression 
of Pitx3 is lost in Pbx1-/-;Pbx3-/- embryos. 
1.6.2 Arntl 
Arntl (aryl hydrocarbon receptor nuclear translocator like, previously known as Bmal1) is a 
member of the basic helix-loop-helix transcription factor gene family. ARNTL is a pioneer 
transcription factor that forms part of the circadian clock machinery in the cell (Menet et al., 
2014; Stevens et al., 2008). Structurally it has a basic helix-loop-helix and two Per-Arnt-Sim 
(PAS) domains. ARNTL binds to CLOCK and form heterodimers that bind to E-boxes in the 
promoters of Per1/2 and Cry1/2 resulting in increasing protein levels, which repress the 
transcriptional activity of ARNTL:CLOCK heterodimers. The regulation of circadian rhythms 
involves additional genes such as Rev-Erb and Ror2, which respective proteins repress or 
induce Arnt1 and are induced by ARNTL:CLOCK (Buhr and Takahashi, 2013).  
Mutations in Arntl have shown an accelerated ageing phenotype in mice (Kondratov et al., 
2006). Interestingly, one of the common non-motor symptoms of PD patients is disturbances 
in sleep, a natural biological process controlled through your circadian rhythm. An abnormal 
circadian clock is shared among many neurodegenerative disorders including Alzheimer’s, 
Huntington’s disease and PD (Hood and Amir, 2017; Musiek and Holtzman, 2016). It has been 
shown that ARNTL, along with another clock protein PERIOD2, controls cell cycle entry and 
exit in during neurogenesis in the adult hippocampus (Bouchard-Cannon et al., 2013) and 
subventricular zone (Malik et al., 2015). Furthermore, it has been shown that ARNTL regulates 
the proneural transcription factor Neurod1 and that Arntl gene silencing reduces the number of 
Map2 positive cells (Kimiwada et al., 2009), suggesting a role in neurogenesis. The role of 
Arntl in mDA neuron development has not been previously studied and it now explored in 
Paper IV. 
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2 AIMS 
This goal of this thesis is to gain knowledge of mDA development by better understanding the 
molecular components and machinery involved in establishing a cellular environment that 
allows for generation of a specific cell type. The ultimate goal is to use this information to 
control the mechanisms governing mDA differentiation in stem cells, which could then be 
directly used in vivo, for PD CRT, or in vitro, to model PD.  
In this thesis, the following questions were addressed. 
• What is the role of Pbx1 in mDA development and how is it implicated in PD? 
• How many cell types are present in the developing VM and in the DA lineage? How 
are they molecularly defined? How different is mouse and human VM development? 
How can we use scRNA-seq information to improve hPSC preparations for PD CRT? 
• How can we extract data from scRNA-seq to better understand the role of new genes 
in mDA development? Have we overlooked additional Wnt signaling components 
present in the developing VM? 
• Can we use a systems-based approach to reveal novel cell intrinsic and cell extrinsic 
candidates critical for mDA neuron development? 
• What is the function of R-Spondins in mDA neuron development? Can they be used to 
promote mDA differentiation of hPSCs and advance stem cell-based CRT for PD? 
• What are the roles of the Wnt/PCP genes Wnt5a, Ror2, and Vangl2 in the development 
of the VM and mDA neurons? 
 
To answer these questions, we have applied several different strategies. Our studies include the 
use of classical developmental methods such as analysis of mutant mice, analysis of PD 
postmortem samples, studies using primary cultures and embryonic stem cells, combined with 
analysis of cell signaling and advanced methods such as scRNA-seq and in silico analysis of 
gene expression.
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3 RESULTS AND DISCUSSION 
3.1 PAPER I: A PBX1 TRANSCRIPTIONAL NETWORK CONTROLS 
DOPAMINERGIC NEURON DEVELOPMENT AND IS IMPAIRED IN 
PARKINSON’S DISEASE 
In this article, we explore the role Pbx1 has in the development and survival of mDA neurons. 
The major findings of this paper (summarized in Figure 6) are: 1) PBX1A expression is first 
acquired in a subset of NR4A2+/TH- cells; 2) Pbx1, and in its absence Pbx3, are required for 
mDA neuron specification, differentiation and survival; 3) PBX1A represses Onecut2 (one cut 
domain, family member 2) to inhibit lateral fates, induces Pitx3 to promote mDA development, 
and induces Nfe2l1 (nuclear factor, erythroid derived 2,-like 1) to protect against oxidative 
stress; 4) A significant reduction in PBX1A and NFE2L1 was detected in the nuclei of SNc 
mDA neurons in post-mortem samples of PD patients; 5) Overexpression of Pbx1 in human 
neuroepithelial stem cells prevented the loss of DA neurons by oxidative stress. Together, our 
results show a function of PBX1 in mDA neuron development, suggest a role in PD and may 
have implications for the development of regenerative medicine and drug development for PD. 
 
Figure 6: Role of PBX1 in ventral midbrain development and Parkinson’s disease 
Graphical summary of results showing stages of PBX1A expression, first appearing in mDA neuroblast 2 (Nb2) 
within the IZ prior to TH expression. PBX1A was found to target Onecut2 to inhibit lateral fates, Pitx3 to promote 
differentiation, and Nfe2l1 for mDA survival. In PD patient samples, decreased levels of NFE2L1 and PBX1A 
were found in SNc DA neurons (Figure adapted from Villaescusa et al., 2016). 
 
Previous studies on Pbx1a in VM development have either examined the expression or levels 
of this transcription factor in mouse embryonic and human fetal tissue or have focused on the 
axonal guidance phenotype in Pbx1 null mice (Sgadò et al., 2012). Here we examined and 
defined the expression of the Pbx1-3, Prep1-2 and Meis1-2. We found that PBX1A appears in 
mDA NR4A2+ neuroblasts, but prior to PITX3 in TH+ mDA neurons. Using knockout mice, 
 28 
we observe an increase in the expression of Pbx3 in Pbx1 null mice, suggestive of a 
compensation. Conditional deletion of Pbx1 in the context of Pbx3-/- mice, revealed a 
misspecification of mDA neurons and a decrease in mDA neuron numbers at later embryonic 
stages. Moreover, lentiviral mediated overexpression of Pbx1 increased the number of TH+ 
cells. Lastly, direct clinical relevance was obtained by examining post mortem VM tissue from 
PD patients, where we found that the levels of PBX1 and NFE2L1 were reduced in the 
remaining SNc mDA neurons, but not in adjacent cell types. 
Analysis of the molecular mechanism by which PBX1 regulates these functions was done with 
chromatin immunoprecipitation sequencing (ChIP-seq). ChIP-seq analysis identified binding 
motifs in proximity to genes related with signal transduction, RNA metabolic processes, 
transcription and response to stress as seen through Gene Ontology terms. After combining 
ChIP-seq data with TruSeq data, by Gene Set Enrichment Analysis (GSEA), target genes of 
Pbx1 were identified to be differentially expressed in the VM. Producing a total of 29 genes 
that were either differentially upregulated of downregulated. Although a select few were 
validated, it still remains to be investigated the role of other target genes on the list and their 
possible role in mDA development. The dual function of PBX1 as an enhancer and repressor 
was briefly explored using bioinformatical analysis to show overrepresented transcription 
factor binding sites in which, for example, repressor loci were enriched on binding sites of 
NR4A2, hinting at the possibility that PBX1/NR4A2 repress common genes. On the other 
hand, the discovery of a Pbx1-Nfe2l1 pathway that is affected in PD patients could open new 
developments into disease modeling and drug discovery. Together, we hereby describe a novel 
function of Pbx1 in the specification and survival of mDA neurons and suggest that the Pbx1-
Nfe2l1 pathway is impaired in PD. More investigations into the mechanisms and possible 
therapeutic application of these findings are warranted. 
3.2 PAPER II: MOLECULAR DIVERSITY OF MIDBRAIN DEVELOPMENT IN 
MOUSE, HUMAN AND STEM CELLS 
In this article, we explore the cellular heterogeneity of the developing mouse and human VM 
at the single-cell level giving us data sets that can give insight into developmental programs 
that can be applied to CRT for PD. The major findings of this paper (some summarized in 
Figure 7) are: 1) A complete VM scRNA-seq data set that encompasses early mDA 
development in both mouse and human was obtained. 2) Novel cell types including three types 
of mouse and five types of human radial glia-like cells biased towards distinct fates were found. 
3) Differences in cell types and gene expression between mouse and human mDA neuron 
development. 4) Single-cell analysis of mature mDA neurons showing five distinct clusters, 
emerging only postnatally. 5) A machine learning method to score mDA differentiation of stem 
cells was developed. Together, our data provides both the information and the methods required 
to assess the performance of DA differentiation protocols at a single-cell level. Our study 
describes mouse and human VM development in vivo, at a transcriptome level, which can be 
applied both to improve the mDA differentiation of hPSC and CRT protocols for PD, as well 
as the development of improved in vitro models of PD and its application in drug screening. 
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Figure 7: Single-cell analysis of developing ventral midbrain 
Graphical scheme of single-cell analysis of mDA lineage in vivo and mDA differentiation of hPSCs in vitro. 
scRNA-seq was performed in embryonic mouse and fetal human VM tissue to perform a cross-species 
comparison. Several cell types in the mDA lineage were identified by the expression of distinct set of genes. Two 
embryonic mDA neurons were found to diversify into five cell types postnatally. Differentiated human ES and 
human iPS cells were compared to the cell types discovered in the in vivo human fetal data set. Using machine 
learning, we developed a method to score the quality of the in vitro differentiated cells.  
 
In this study, we took advantage of cutting edge technologies such as scRNA-seq and new 
bioinformatical analysis methods to explore the cell types and molecular composition of the 
embryonic mouse and human fetal tissue. We generated a data set encompassing the critical 
time window when mDA neurogenesis takes place and generated a library of 1,977 human fetal 
cells, 1,907 mouse embryonic cells, 245 postnatal murine cells, and additionally, 2,052 cells 
hPSCs during their differentiation into mDA neurons in vitro. Using Back-SPIN clustering on 
the in vivo data sets we obtained 25 human and 26 mouse clusters that were largely conserved 
across species. By using unique molecular identifiers in our scRNA-seq analysis we were able 
to reveal the identity of cells based on their relative gene expression levels.  
Focusing on the mDA lineage, we found from early neural progenitors, to neuroblasts and 
several post-mitotic embryonic DA cell types. Evaluating this sequential process, we 
discovered that each maturation step results from the acquisition of additional gene expression 
rather than their loss. To our surprise, the emergence of mature mDA neuron populations was 
not detected postnatally. mDA neurons have been previously classified by their electrical 
properties, anatomical position, and a handful of markers. With scRNA-seq technology, we are 
able to provide a complete unbiased evaluation of cell types at a molecular level. We discovered 
two mature fetal mDA neuron subtypes subdivide into five populations postnatally. This was 
validated with immunofluorescence where the five populations, such as one SNc and four VTA 
mDA neurons only emerged at P7. This is interesting due to the fact that PD specifically 
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impairs the function and survival of SNc neurons. In addition, finding the earliest decision a 
cell has to make to differentiate into a SNc mDA neuron may contribute to develop specific 
hPSC differentiation protocols for SNc neurons and improve thus CRT for PD.  
Another interesting aspect of this paper was that we provide a tool to aid in the evaluation of 
hPSC-derived mDA neurons for CRT. All current evaluation techniques usually involve using 
a handful of gene markers to show the percentage of cells in the culture that are positive for 
these markers and then functional evaluations in vitro followed by in vivo assessment of their 
capacity to recover motor function after transplantation in PD mouse models. Although several 
studies claim a high percentage of cells in the mDA lineage, these preparations still contain 
multiple cell types belonging to other compartments and serving other functions. In addition, 
the critical question of what is the complete identity and functional capacity of cells 
unidentified as dopaminergic in these studies still remains to be answered. Using scRNA-seq, 
a global perspective and a very detailed level of information can be obtained at the same time, 
allowing to evaluate all the cell types present in the culture. As an example, in this paper, our 
evaluation of hPSC-derived mDA neurons revealed the presence of a near complete VM tissue 
containing unnecessary cell types for cell replacement such as GABAergic and red nucleus 
neurons, but also undesired cell types, such as hindbrain serotonin neurons that may cause 
graft-induced dyskinesias. Our study also raises the question of whether or not having a pure 
culture is important and whether or not some of additional cell types may be actually good to 
provide support to mDA neurons. Extensive testing would need to be done in the future. Either 
way, our machine learning tool can be used to examine the quality of hPSC-derived cells 
obtained by new protocols, which will be essential to improve cell preparations and to move 
forward the field of CRT for PD.  
 
3.3 PAPER III: TRANSLATION OF WNT DEVELOPMENTAL PROGRAMS IN TO 
STEM CELL REPLACEMENT STRATEGIES FOR THE TREATMENT OF 
PARKINSON’S DISEASE 
In this article, we review the role of WNT in the developing midbrain and extract new 
information from single-cell data acquired in Paper II. The major points of this review are: 1) 
We provide an overview of current knowledge on WNTs in mDA development and how they 
have been implemented into current hPSC differentiation protocols. 2) We reveal new WNT 
signaling components present in the developing human fetal VM development. 3) We discuss 
the possible importance of these new findings for mDA neuron development and for improving 
current hPSC mDA differentiation protocols and CRT for PD. A summary of this article is 
shown in Figure 8.  
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Figure 8: Expression of WNTs and related signaling components as well as their distribution in the human 
ventral midbrain 
A) Cartoon summarizing the current knowledge of the functions of Wnt1 and Wnt5a in the mDA lineage during 
embryonic development based on in vitro and in vivo mouse data. B) Heat map of Wnts and Wnt signaling 
modulators found in the developing human VM in representative cell types revealed through scRNA-seq. C) 
Schematic representation of localization of Wnts and Wnt modulators found in Panel B (Figure adapted from 
Toledo et al., 2017).  
 
Using the in vivo data set generated from human fetal tissue in Paper II, we were able to 
analyze distinct components of different signaling pathways. Here we focused on the ligands 
and modulators of the Wnt pathway expressed in the human dataset, including WNTs, SFRPs, 
and DKKs. As mentioned previously, the two critical ligands in VM development are WNT1 
and WNT5A and beyond these, very little has been explored about the function of other 
possible players. Even less in known about human development, where in addition of the 
known expression of WNT1 and WNT5A, we found the expression of WNT7A, WNT7B, 
WNT8B and WNT11, and Wnt signaling modulators (SFRP1, SFRP2, and DKKs) in various 
human VM cell types.  
Moving forward, we think that careful manipulation of the Wnt pathway, especially the 
interplay between Wnt/β-catenin dependent and Wnt/PCP pathways, will be important in mDA 
specification for SNc type neurons. The location of Wnt signaling components and their 
influence on surrounding cell types could be critical due to the possibility that SNc neurons 
emerge from a distinct population compared to VTA in the developing VM. Interesting 
candidates for future studies include WNT8B due to its exclusive expression in radial glia-like 
1 cell type (Rgl1), believed to be the neurogenic progenitor. However, it should be noted that 
nearly all the ligands and modulators of Wnt signaling found in our data sets are potentially 
interesting, regardless of the cell type of origin as the factors work both in an autocrine and 
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paracrine manners, affecting neighboring cells in the midbrain floor plate niche, where mDA 
neurons emerge. 
Of interest for this thesis is also Wnt5b, a Wnt not included in this review since it was only 
found in the mouse data. We found that Wnt5b is expressed in progenitor cells, together with 
Wnt5a, suggesting the Wnt5b may be able to compensate for the loss of Wnt5a in the Wnt5a-/- 
mice, a possibility that remains to be examined.  
In summary, the review presented here is only a small piece of what is possible to do with 
regard to the analysis of scRNA-seq data. Here, we only examined secreted factors of the Wnt 
signaling pathway. Other typical or non-typical Wnt signaling modulators such as Tpbg, 
Apcdd1, and Trabd2a showed interesting expression dynamics in the mDA lineage, but were 
not analyzed. Similarly, we did not consider receptors or tried to match cell types expressing 
receptor-ligand as the complexity of such networks grows exponentially. This type of analysis 
was performed in Paper IV. We conclude that in silico analysis can be used to systematically 
examine signaling components in candidate pathways that can then be then studied with 
experimental biological methods. 
 
3.4 PAPER IV: MOLECULAR ANALYSIS OF MIDBRAIN DOPAMINERGIC 
NICHE DURING NEUROGENESIS 
In this article, we explore the cell types and the signals that contribute to mDA neurogenesis. 
Using data from Paper II, additional VM bulk RNA-seq data and through bioinformatical 
analysis we define the concept of the mDA niche, that is the cell types and genes contributing 
to mDA neurogenesis. The main points of the study are: 1) The cell type contributing the most 
to mouse mDA neurogenesis was radial glia type 1 (Rgl1) identified in Paper II. 2) Analysis 
of cell extrinsic components identified participation of several cell types in the formation of the 
mDA niche, of which Rgl3 is the cell type expressing most ECM components and ligands for 
diverse signaling pathways for a specific VM niche. 3) Analysis of cell intrinsic factors 
identified different transcriptional networks in each of the three radial glia types and congruent 
with specific function for each radial glia. 4) Based on the analysis above we examine the 
function of the transcription factor Arntl, a central transcription factor in the pro-neurogenic 
network identified in Rgl1, and found a novel function of Arntl in controlling mDA 
neurogenesis. Results are summarized in Figure 9. 
We started our study with the analysis of midbrain tissue and four adjacent brain regions from 
E11.5-E14.5, to define genes differentially expressed in the VM. The samples were also 
analyzed with weighted gene co-expression analysis where different gene modules were 
discovered and described different aspects of midbrain development as seen through gene 
ontology analysis. We further describe in detail a specific mDA module enriched in 
differentially expressed genes of the VM, which also is enriched in genes that describe different 
molecular processes, such as ECM formation. We then integrated the single-cell data from 
Paper II in order to identify the cell types contributing to the mDA module. Radial glia have 
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previously been reported to be part of the mDA lineage (Bonilla et al., 2008) and in our data 
represented a distinct cell type contributing the most to the ECM and its regulatory elements. 
We also develop a methodology to determine the main contributing cell types on a biological 
process. We analyzed both ligands and receptors for different developmental signaling 
pathways which included in addition to endothelial cells, pericytes and microglia, all the three 
radial glia types.  
 
Figure 9: The ventral midbrain dopaminergic niche 
Graphical abstract showing the transcriptional networks of the three types of radial glia (mRgl1-3) showing their 
contribution to the ECM core components, ECM modifiers, and ligands. Together, they contribute to a 
microenvironment in which mDA neurons emerge, the mDA niche. Furthermore, Rgl1, the putative radial glia in 
the mDA lineage, was characterized by a transcriptional network centered on the transcription factor ARNTL, 
which we found controls DA neurogenesis in human neuroepithelial stem cells.  
 
Our approach suggests different functions for each of the radial glia (Rgl1-3) that contribute to 
mDA neurogenesis and the mDA niche and express known developmental signals and factors. 
Rgl1 expressing transcription factors required for mDA neurogenesis, Rgl2 expressing 
transcription factors for progenitor maintenance, and Rgl3 expressing transcription factors for 
formation of the mDA niche including ECM components. Together, we suggest a model in 
which Rgl1 serves as a neurogenic progenitor and reveal a transcriptional network centered 
around pioneering factor ARNTL, which controls cell cycle duration and here, progress into the 
mDA lineage. Using transcriptome data from the developing VM, we describe the mDA niche 
in which cells arise and the regulatory transcriptional networks involved in the setting up and 
maintenance of this environment.  
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3.5 PAPER V: THE MATRICELLULAR PROTEIN R-SPONDIN 2 (RSPO2) 
PROMOTES MIDBRAIN DOPAMINERGIC NEURON NEUROGENESIS AND 
DIFFERENTIATION 
In this manuscript, we examine the role of a Wnt signaling regulator RSPOs. A lot of literature 
points to the fact that RSPOs potentiates Wnt signaling. We here investigate how RSPOs can 
be used in stem cell differentiation protocols in order to differentiate mDA neurons more 
effectively. Our findings include: 1) Exclusive expression of Rspo2 during VM development. 
2) RSPO2 has a significant effect on the differentiation of mDA neurons in mouse primary 
cultures as well as on the differentiation of mouse embryonic stem cells. 3) RSPO2 also has a 
significant effect on the differentiation of human ES cells into mDA neurons but was found to 
have an additional effect on mDA neurogenesis, which is of interest in order to improve cell 
preparations to be used in CRT for PD. Together, this data provides evidence that additional 
manipulations of the Wnt signaling pathway in vitro may contribute to improve current mDA 
differentiation protocols. 
Previous reports have suggested a function of Rspo2 in a sub-population of mDA neurons and 
a regulation by Lmx1a (Hoekstra et al., 2013). We hereby examine the expression and function 
of different spondins in the developing VM. We found that Rspo2 is strongly expressed in the 
developing VM during neurogenesis and we thus decided to apply recombinant RSPO2 protein 
to determine its biological activity in mouse primary VM, mouse ES, and human ES cell 
cultures. All cultures treated with RSPO2 showed a robust significant increase in 
differentiation, as shown by an increase in the proportion of NR4A2+ cells that become and 
TH+. We found that this effect was exclusive for RSPO2, a protein that induced and additional 
increase in the number of the first postmitotic cell in the mDA lineage, the NR4A2+ cells.  
Previous studies have shown that the implementation of Wnt signaling in differentiation 
protocols is essential for proper specification of midbrain progenitors (Kirkeby et al., 2012; 
Kriks et al., 2011). Here, early activation of Wnt/β-catenin signaling was already used to 
improved mDA differentiation in hPSCs, as it is standard in the field. However, we found that 
a later manipulation of Wnt/β-catenin signaling with RSPO2 further improved neurogenesis 
and differentiation. It is important to note that currently protocols for hPSC-differentiation into 
mDA neurons use very high doses of GSK3β inhibitors, which have off target effects 
(discussed in Paper III). One possibility to improve such protocols would be to use RSPO2 at 
early stages to minimize these. Additionally, RSPOs have been critical in the setting up of 
organoids in other systems like the gut and liver and it would thus be of interest to examine 
whether RSPO2 could be also used to improve midbrain organoids. Furthermore, it remains to 
be determined whether RSPO2 can aid in the specification of SNc neurons, the cell type lost in 
PD. 
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3.6 PAPER VI: ROR2 AND VANGL2 CONTROL DOPAMINERGIC 
NEUROGENESIS AND MULTIPLE ASPECTS OF CELL POLARITY IN THE 
MIDBRAIN FLOOR PLATE 
In this manuscript, we investigate the function of Wnt/PCP signaling components in VM 
development. Using mouse models, we find that the Wnt/PCP components, Ror2 and Vangl2 
play essential roles in different aspects of mDA development that go beyond that of previous 
functions identified in Wnt5a-/- mice. These include: 1) Wnt5a overexpressing embryos 
partially phenocopy Wnt5a-/-, affecting morphogenesis and mDA differentiation. 2) Double 
compound mutant mice for Wnt5a and its receptor Ror2 reveal stronger morphogenesis defect 
than that of Wnt5a-/- embryos. 3) Double compound mutant embryos for the Wnt/PCP signaling 
components, Ror2 and Vangl2, reveal novel alterations in mDA development including a very 
severe morphogenic defect with collapse of the ventricle and right-left asymmetry and 
reduction in mDA neurogenesis resulting in a significant reduction in the production of mDA 
neurons. 
 
Figure 10: Function of Wnt5a, Ror2, and Vangl2 in midbrain and dopaminergic neuron development 
Graphical summary of conclusions obtained from analyzing mutant mice for the Wnt/PCP genes: Wnt5a, Ror2, 
and Vangl2. Previous analysis of Wnt5a mutant mice have shown impairments in VM morphogenesis, progenitor 
proliferation, and mDA differentiation in mice (red). Similarly, Wnt5a overexpressing mice showed clear 
morphogenic defects and alterations in mDA differentiation and mDA neuron migration. Morphogenesis was also 
impaired in Wnt5a;Ror2 mice, to a larger extent than in Wnt5a deficient mice. Ror2;Vangl2 double mutants 
showed an even more severe PCP morphogenesis phenotype and alterations in multiple aspects of mDA neurons 
development, including increase in proliferation and decreases in neurogenesis and differentiation 
 
In this study, we first examined the expression of Ror and Vangl family member during 
development by various methods and found a very dynamic regulation of the expression of 
Vangl2 that correlated with mDA neurogenesis. We then took advantage of a novel transgenic 
mouse line where the expression of Wnt5a can be induced with doxycycline. Our results from 
the analysis of this mice revealed a surprising resemblance to the VM phenotype of the Wnt5a-
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/- mice (Andersson et al., 2008) in that we see clear defects in morphogenesis but also early 
developmental delays that is compensated for at later time points. These findings support the 
hypothesis that the levels of Wnt5a are important for proper VM development. Next, since 
Wnt5a can signal via Ror2 we examined whether double mutant mice for these two genes 
worsened the Wnt5a phenotype. To our surprise, we found only a mild worsening of the 
morphogenesis phenotype of the Wnt5a null phenotype in Ror2-/-;Wnt5a-/- mice embryos, 
although analysis of additional mutant mice is still necessary to complete this study. In 
agreement with previous results showing a cooperation between Ror2 and Vangl2 in limb 
development (Gao et al., 2011), analysis of Ror2;Vangl2 mice revealed a strong Wnt/PCP 
phenotype in the VM, including a clear alteration of morphogenesis and mDA differentiation. 
Ror2-/-;Vangl2-/- embryos also suffered from neural tube closure defects. In addition, we also 
found an alteration in left-right symmetry that altered the distribution of mDA progenitors, 
neuroblasts and neurons. The specification of the floor plate was not disrupted but we found an 
additional novel defect in mDA neurogenesis, as shown by a decrease in the number of 
postmitotic cells in the mDA lineage. Notably, severe morphogenic defects and decreased 
numbers of mDA neurons have not been previously observed in Wnt5a null embryos 
(Andersson et al., 2008). This finding suggests that the ROR2-VANGL2 complex is likely to 
transduce not only the signal from WNT5A, but also from additional Wnts. One likely 
candidate, based on our analysis in Paper III of the scRNA-seq data in Paper II, is that 
WNT5B, expressed in the same cell as WNT5A, may also signal through the same receptor 
complex. Future analysis of double Wnt5a-/-;Wnt5b-/- mice would allow to answer this question. 
In addition it also remains to be determined whether additional Wnt/PCP receptors such as 
Fzd3 and Fzd6 (Stuebner et al., 2010) may also contribute to transduce the Wnt/PCP signal. In 
summary, this study finds novel roles of two Wnt/PCP signaling components in the developing 
VM and contributes to increase our understanding of the complex world of Wnt signaling. 
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4 CONCLUSION 
This thesis is composed of four papers and two manuscripts covering various aspects of mDA 
neuron development. Our goal has been to gain a better understanding of the biological 
processes that govern this process. Based on the work within this thesis, I present the 
following conclusions: 
 
• Pbx1 and in its absence, Pbx3 play a critical role in mDA differentiation and the 
survival of mDA neurons. 
• Single-cell RNA-seq has unraveled a previously unsuspected cellular diversity and 
molecular complexity in the developing VM. 
• Single-cell RNA-seq data allows to identify previously overlooked Wnt signaling 
components in the developing VM. 
• In silico methods can be used to mine single-cell RNA-seq data and characterize cell 
intrinsic and extrinsic factors in the mDA neuron niche.. 
• R-spondin 2 robustly promotes the in vitro differentiation of endogenous mouse or 
human ES cell-derived mDA neurons.  
• The Wnt/PCP membrane proteins Ror2 and Vangl2 control two novel functions in the 
developing VM: mDA neurogenesis and left-right symmetry. 
 
And yet, here we are, 200 years after the publication of An Essay on the Shaking Palsy, still 
revealing critical molecular components and aiding in finding a cure for PD. Like James 
Parkinson, we look forward to a cure for this devastating disease. We just hope it will not take 
another 200 years! 
 
  39 
5 ACKNOWLEDGEMENTS 
Now to the page that is usually opened first by the majority of you. Even though I am not a person of 
many words, it is time to give gratitude for the people that have aided in the completion of what you 
have before you, whether it be scientific or just your presence. As I make this list, I can’t help to notice 
how long I have been here and only a select few left from the first day I stepped into MolNeuro in 2010 
when confocals, cryostats, and cell culture were all located in only our two main corridors.  
Ernest, what do I say, thanks to giving me something to write about. Thank you for taking me in and 
believing in me. The PhD would not have been the same without your guidance and drive for science, 
pushing the difficult questions and seeing where they lead. It has been a pleasure to see the work you 
do, pushing through obstacles and finding a way and getting rewarded for it. I can’t thank you enough, 
but thank you. 
Carlos, it has been a joy working with you and the talent that you have. You are a true testament of not 
giving up on your research and thank you for your guidance from the very beginning. I wish you all the 
best with your new step in your career.  
Sten, working with you throughout the years on DDPDGENES and watching how your lab evolved so 
quickly over the years is truly remarkable. The field has evolved so quickly yet you manage to stay in 
the front all these years and at this rate there are no barriers in your way. 
Enrique, where do I start? The walking encyclopedia of useless knowledge and the only person in the 
unit that not only knows what technique should be used to answer your scientific questions but also 
what the purpose of every reagent used is. At least I know I will always be able to fix your English. 
As a person who likes to figure things out himself instead of going for help, there are a few things that 
I could not have done without you Alessandra. MolNeuro would not function without you, so thank 
you, especially these last few months! 
Johnny, you left a hole in MolNeuro when you left and I think I can speak for everyone that MolNeuro 
is just different without you. Thank you so much for all the work you did in the lab even when you think 
it goes unnoticed sometime. The gratitude you deserve in all our projects is beyond fathomable, so 
wherever you are enjoying your free time, Thank YOU! And to Ahmad, for your continued support of 
entire MolNeuro when Johnny left, thank you. 
To the EA group lab members past and present. Carmen, for all your enthusiasm even when things 
don’t go as expected. Shanzheng, for always surprising me with your scientific questions. Alca, for 
being my lab bench neighbor, hope you have a strong end to your PhD. Dawei, for your Swedish 
conversations. Kaneyasu, for your kindness and last bit of help on our project. Lottie, for your help in 
organizing the lab and our Swedish conversations at our benches. Chika, for your never endless cheerful 
aura. Pia, for proving big things can be accomplished when working hard for it. To the other members 
I have come across during my time: Spyros, Catarina, Lukas, Diogo, Isabel, Willy, Geeta, Mark, 
and Fabia, I wish you all the best and thanks for making the EA lab what it is. And not to forget pseudo-
member Karol, providing me with endless western blots to laugh at.  
Now to fellow colleagues far and wide. It has been a pleasure to get to know the people in my office 
and have myself be the veteran there now. For the past members of the office, Saida, Moritz, Helena, 
and Marina, thanks for taking me in even though you probably didn’t notice me for my quietness. And 
 40 
for the current inhabitants, Carolina, you are looking kind of weak, hopefully the science works out 
better than the gym. Viktoria, for always having something to complain about with me. Martin, I see 
it as an accomplishment that we are not facebook friends yet. Sam, I never would have thought that I 
would not be the quietest one in the office. Jose, well you probably won’t read this, I’m sure you are 
just staring at your computer anyways. Office people, I just hope you all can survive without my 
Illustrator skills and best of luck to you all. 
Special thanks to Gioele, the project we had evolved quickly into something bigger than we imagined. 
I never knew so much could be done sitting at your computer all day. Your inquisitive mind will do 
great things, best of luck to you. And Amit, it has been without a doubt a pleasure to see the never-
ending drive of science you have, even me doing experiments for you on New Year’s Day and seeing 
you in the lab every weekend since you have been here, best of luck to your next step in your career and 
family life. 
To some of the other people lingering around MolNeuro. Daga, for having a sixth sense and knowing 
what I am thinking without me saying anything. Lars for keeping me curious on what new tinker toy 
you are building next. David, proving it doesn’t matter how tall you stand as long as you know how to 
make a poster. Hermany, for always having an opinion to listen to and giving me a reason to be quiet. 
Best of luck on your PhDs. Thanks to the MolNeuro ladies I have gotten to know over the years past 
and present, Fatima and lab mascot Lilian for cryostat CPR. Ana F, Ana M, Elisa, Sueli, and Hannah, 
I’m sure we will be seeing more of each other in the future. And to the ones that have been here since 
the beginning, the old timers, Boris (don’t worry, you still look young to me), Simone, Songbai, and 
Dmitry it has been a pleasure to walk these halls all these years with you. To the few Swedes that 
accepted me as their own, Anna, Ivar, Kasra and Erik, although I don’t think I have convinced any of 
you of my Swedish identity. Göran for your support on the confocals and Connla for showing me boats 
go backwards too. Thanks to some of the past member of MolNeuro that I have been grateful to get to 
know, Kasper, Blanchi, Alessandro, Francois and Saiful. And for some of you outside of MolNeuro, 
Nigel proving your scientific nemesis can be friends. German, I know where I will run into you. Kim, 
Christina, Maryam, it has been a pleasure to get to know you to realize there is more than just a lab in 
the real world. To my other friends from a past life who I keep in touch with and will forever remain 
friends, thanks. 
To the second generation of MolNeuro PIs. Jens, Gonçalo, and Ulrika, the enthusiasm and passion you 
all have for your various interests is what defines the environment of MolNeuro and has only made it 
an even more enjoyable place to work at. I wish you all the best in your careers. 
To the more senior PI’s, Patrik and Per, who helped build MolNeuro to what it is today. An 
environment of great diversity of hard working people, pushing research to the limits and setting an 
example for many to follow, thank you.  
To the rest of MolNeuro, thanks for everything, whether the interaction was big or small. Over the years 
people have come and gone but MolNeuro doesn’t change.  
The Scheele Facility staff, in particular Nadia. It has been many years and could not ask for a better 
caretaker. I wish you all the best in the future and can’t thank you enough. I would also like to thank 
Therese for her help in my last few months here. And to Margareta and Theresa for running such an 
ordered facility, as well as the rest of staff for your continued support over the years. 
  41 
To all my collaborators, it has been a pleasure to help in developing and completing projects and being 
a part of them has been most grateful. From the early days at MolNeuro, Igor and Marketa, the talent 
you have and the crazy ideas you come up with are the least bit fascinating and curious people like you 
are what drives science to the limits. Roger and Simon, thanks for exposing me to another side of the 
PD field and for your immense contribution to our project. Renee and Max for making my projects 
more well-rounded and would not be the same without your scientific contributions. 
I would like to thank my opponent, Prof. Salinas for her time in evaluating my thesis and the discussion 
we will have. I would like to thank the examination board Prof. Svenningsson, Prof. Muhr, and Prof. 
Landegren for your time and participation in the defence of my thesis.  
And to Mandy, min sötis. Thanks for the support the last few years and all the memories we have 
together. I hope we share many more. I will be looking forward to the writing of your thesis :). 
And to my family. Mamma och Pappa, tack för allt stöd från dag ett. Möjligheterna du har gett oss 
från början kan aldrig tackas nog. Alla reser runt om i världen har visat oss mycket och lärt oss så mycket 
mer. Även om vi ibland hade kontinenter mellan oss, visste jag att det aldrig skulle vara möjligt utan ni 
två. Och vem skulle ha trott de oändliga söndags utflykterna till svensk skola skulle ha blivit bra till 
nytta. Ni kanske förstår fortfarande inte vad jag gör men tack för allt, kyss och kram. Och till mina 
bröder, Mattias och Marcus, tack för alla aventyr vi har varit med på under åren och ert stöd. 
To whomever I missed I apologize, and fellow colleagues, you are in good hands at MolNeuro and it 
would be hard to find something similar anywhere else. Well I told myself I would keep my 
acknowledgements to one page…Words can’t express the appreciation everyone here deserves, but 
Thank You all! 
 
 
  43 
6 REFERENCES 
Abeliovich, A., and Gitler, A.D. (2016). Defects in trafficking 
bridge Parkinson’s disease pathology and genetics. Nature 539, 
207–216. 
Afzal, A.R., and Jeffery, S. (2003). One gene, two phenotypes: 
ROR2 mutations in autosomal recessive Robinow syndrome and 
autosomal dominant brachydactyly type B. Hum. Mutat. 22, 1–11. 
Agid, Y., Ruberg, M., Dubois, B., Pillon, B., Cusimano, G., 
Raisman, R., Cash, R., Lhermitte, F., and Javoy-Agid, F. (1986). 
Parkinson’s disease and dementia. Clin. Neuropharmacol. 9 Suppl 
2, S22-36. 
Al-Shawi, R., Ashton, S. V., Underwood, C., and Simons, J.P. 
(2001). Expression of the Ror1 and Ror2 receptor tyrosine kinase 
genes during mouse development. Dev. Genes Evol. 211, 161–
171. 
Almqvist, P.M., Akesson, E., Wahlberg, L.U., Pschera, H., Seiger,  
a, Sundstrom, E., Åkesson, E., Wahlberg, L.U., Pschera, H., 
Seiger, Å., et al. (1996). First trimester development of the human 
nigrostriatal dopamine system. Exp. Neurol. 139, 227–237. 
van Amerongen, R., and Nusse, R. (2009). Towards an integrated 
view of Wnt signaling in development. Development 136, 3205–
3214. 
van Amerongen, R., Mikels, A., and Nusse, R. (2008). Alternative 
wnt signaling is initiated by distinct receptors. Sci. Signal. 1, re9. 
Van Amerongen, R., Fuerer, C., Mizutani, M., and Nusse, R. 
(2012). Wnt5a can both activate and repress Wnt/β-catenin 
signaling during mouse embryonic development. Dev. Biol. 369, 
101–114. 
Anderegg, A., Lin, H.-P., Chen, J.-A., Caronia-Brown, G., 
Cherepanova, N., Yun, B., Joksimovic, M., Rock, J., Harfe, B.D., 
Johnson, R., et al. (2013). An Lmx1b-miR135a2 regulatory circuit 
modulates Wnt1/Wnt signaling and determines the size of the 
midbrain dopaminergic progenitor pool. PLoS Genet. 9, e1003973. 
Andersson, E., Tryggvason, U., Deng, Q., Friling, S., Alekseenko, 
Z., Robert, B., Perlmann, T., and Ericson, J. (2006). Identification 
of intrinsic determinants of midbrain dopamine neurons. Cell 124, 
393–405. 
Andersson, E.R., Prakash, N., Cajanek, L., Minina, E., Bryja, V., 
Bryjova, L., Yamaguchi, T.P., Hall, A.C., Wurst, W., and Arenas, 
E. (2008). Wnt5a regulates ventral midbrain morphogenesis and 
the development of A9-A10 dopaminergic cells in vivo. PLoS One 
3, e3517. 
Andersson, E.R., Saltó, C., Villaescusa, J.C., Cajanek, L., Yang, 
S., Bryjova, L., Nagy, I.I., Vainio, S.J., Ramirez, C., Bryja, V., et 
al. (2013). Wnt5a cooperates with canonical Wnts to generate 
midbrain dopaminergic neurons in vivo and in stem cells. Proc. 
Natl. Acad. Sci. U. S. A. 1–9. 
Andre, P., Wang, Q., Wang, N., Gao, B., Schilit, A., Halford, 
M.M., Stacker, S.A., Zhang, X., and Yang, Y. (2012). The Wnt 
coreceptor Ryk regulates Wnt/planar cell polarity by modulating 
the degradation of the core planar cell polarity component Vangl2. 
J. Biol. Chem. 287, 44518–44525. 
Andre, P., Song, H., Kim, W., Kispert, A., and Yang, Y. (2015). 
Wnt5a and Wnt11 regulate mammalian anterior-posterior axis 
elongation. Development dev.119065-. 
Arenas, E. (2014). Wnt signaling in midbrain dopaminergic neuron 
development and regenerative medicine for Parkinson’s disease. J. 
Mol. Cell Biol. 6, 42–53. 
Arenas, E., Denham, M., and Villaescusa, J.C. (2015). How to 
make a midbrain dopaminergic neuron. Development 142, 1918–
1936. 
Arendt, D. (2008). The evolution of cell types in animals: 
emerging principles from molecular studies. Nat. Rev. Genet. 9, 
868–882. 
Astudillo, P., Carrasco, H., and Larraín, J. (2014). Syndecan-4 
inhibits Wnt/β-catenin signaling through regulation of low-density-
lipoprotein receptor-related protein (LRP6) and R-spondin 3. Int. J. 
Biochem. Cell Biol. 46, 103–112. 
Bacher, R., and Kendziorski, C. (2016). Design and computational 
analysis of single-cell RNA-sequencing experiments. Genome 
Biol. 17, 63. 
Baker, N.E. (1987). Molecular cloning of sequences from 
wingless, a segment polarity gene in Drosophila: the spatial 
distribution of a transcript in embryos. EMBO J. 6, 1765–1773. 
Barker, R. a, Drouin-Ouellet, J., and Parmar, M. (2015). Cell-
based therapies for Parkinson disease—past insights and future 
potential. Nat. Rev. Neurol. 11, 492–503. 
Bayer, S. a, Wills, K. V, Triarhou, L.C., and Ghetti, B. (1995). 
Time of neuron origin and gradients of neurogenesis in midbrain 
dopaminergic neurons in the mouse. Exp. Brain Res. 105, 191–
199. 
Bell, S.M., Schreiner, C.M., Wert, S.E., Mucenski, M.L., Scott, 
W.J., and Whitsett, J. a (2008). R-spondin 2 is required for normal 
laryngeal-tracheal, lung and limb morphogenesis. Development 
135, 1049–1058. 
Berwick, D.C., and Harvey, K. (2012). The importance of Wnt 
signalling for neurodegeneration in Parkinson’s disease. Biochem. 
Soc. Trans. 40, 1123–1128. 
Bhanot, P., Brink, M., Samos, C.H., Hsieh, J.C., Wang, Y., Macke, 
J.P., Andrew, D., Nathans, J., and Nusse, R. (1996). A new 
member of the frizzled family from Drosophila functions as a 
Wingless receptor. Nature 382, 225–230. 
Binnerts, M.E., Kim, K.-A., Bright, J.M., Patel, S.M., Tran, K., 
Zhou, M., Leung, J.M., Liu, Y., Lomas, W.E., Dixon, M., et al. 
(2007). R-Spondin1 regulates Wnt signaling by inhibiting 
internalization of LRP6. Proc. Natl. Acad. Sci. U. S. A. 104, 
14700–14705. 
Björklund, A., and Dunnett, S.B. (2007). Dopamine neuron 
systems in the brain: an update. Trends Neurosci. 30, 194–202. 
Blaess, S., and Ang, S.-L. (2015). Genetic control of midbrain 
dopaminergic neuron development. Wiley Interdiscip. Rev. Dev. 
Biol. 4, 113–134. 
Blakely, B.D., Bye, C.R., Fernando, C. V, Prasad, A.A., 
Pasterkamp, R.J., Macheda, M.L., Stacker, S.A., and Parish, C.L. 
(2013). Ryk, a receptor regulating Wnt5a-mediated neurogenesis 
and axon morphogenesis of ventral midbrain dopaminergic 
neurons. Stem Cells Dev. 22, 2132–2144. 
Bock, O. (2013). Cajal, Golgi, Nansen, Schäfer and the neuron 
doctrine. Endeavour 37, 228–234. 
Bodea, G.O., and Blaess, S. (2015). Establishing diversity in the 
dopaminergic system. FEBS Lett. 589, 3773–3785. 
Bodea, G.O., Spille, J.-H., Abe, P., Andersson, A.S., Acker-
Palmer, A., Stumm, R., Kubitscheck, U., and Blaess, S. (2014). 
Reelin and CXCL12 regulate distinct migratory behaviors during 
the development of the dopaminergic system. Development 141, 
661–673. 
Bonifati, V. (2014). Genetics of Parkinson’s disease--state of the 
art, 2013. Parkinsonism Relat. Disord. 20 Suppl 1, S23-8. 
Bonilla, S., Hall, A.C., Pinto, L., Attardo, A., Götz, M., Huttner, 
 44 
W.B., and Arenas, E. (2008). Identification of midbrain floor plate 
radial glia-like cells as dopaminergic progenitors. Glia 56, 809–
820. 
Bota, M., and Swanson, L.W. (2007). The neuron classification 
problem. Brain Res. Rev. 56, 79–88. 
Bouchard-Cannon, P., Mendoza-Viveros, L., Yuen, A., Kærn, M., 
and Cheng, H.M. (2013). The circadian molecular clock regulates 
adult hippocampal neurogenesis by controlling the timing of cell-
cycle entry and exit. Cell Rep. 5, 961–973. 
Braak, H., Del Tredici, K., Rüb, U., de Vos, R.A.I., Jansen Steur, 
E.N.H., and Braak, E. (2003). Staging of brain pathology related to 
sporadic Parkinson’s disease. Neurobiol. Aging 24, 197–211. 
Braak, H., Sastre, M., Bohl, J.R.E., de Vos, R.A.I., and Del 
Tredici, K. (2007). Parkinson’s disease: lesions in dorsal horn layer 
I, involvement of parasympathetic and sympathetic pre- and 
postganglionic neurons. Acta Neuropathol. 113, 421–429. 
Bryja, V., Schulte, G., Rawal, N., Grahn, A., and Arenas, E. 
(2007). Wnt-5a induces Dishevelled phosphorylation and 
dopaminergic differentiation via a CK1-dependent mechanism. J. 
Cell Sci. 120, 586–595. 
Buhr, E.D., and Takahashi, J.S. (2013). Molecular components of 
the Mammalian circadian clock. Handb. Exp. Pharmacol. 7, 3–27. 
Bye, C.R., Thompson, L.H., and Parish, C.L. (2012). Birth dating 
of midbrain dopamine neurons identifies A9 enriched tissue for 
transplantation into parkinsonian mice. Exp. Neurol. 236, 58–68. 
Cabrera, C. V., Alonso, M.C., Johnston, P., Phillips, R.G., and 
Lawrence, P.A. (1987). Phenocopies induced with antisense RNA 
identify the wingless gene. Cell 50, 659–663. 
Carmon, K.S., Gong, X., Lin, Q., Thomas, A., and Liu, Q. (2011). 
R-spondins function as ligands of the orphan receptors LGR4 and 
LGR5 to regulate Wnt/beta-catenin signaling. Proc. Natl. Acad. 
Sci. U. S. A. 108, 11452–11457. 
Castelo-Branco, G., Wagner, J., Rodriguez, F.J., Kele, J., Sousa, 
K., Rawal, N., Pasolli, H.A., Fuchs, E., Kitajewski, J., and Arenas, 
E. (2003). Differential regulation of midbrain dopaminergic 
neuron development by Wnt-1, Wnt-3a, and Wnt-5a. Proc. Natl. 
Acad. Sci. U. S. A. 100, 12747–12752. 
Castelo-Branco, G., Rawal, N., and Arenas, E. (2004). GSK-3beta 
inhibition/beta-catenin stabilization in ventral midbrain precursors 
increases differentiation into dopamine neurons. J. Cell Sci. 117, 
5731–5737. 
Castelo-Branco, G., Andersson, E.R., Minina, E., Sousa, K.M., 
Ribeiro, D., Kokubu, C., Imai, K., Prakash, N., Wurst, W., and 
Arenas, E. (2010). Delayed dopaminergic neuron differentiation in 
Lrp6 mutant mice. Dev. Dyn. 239, 211–221. 
Cenci, M.A. (2007). Dopamine dysregulation of movement control 
in L-DOPA-induced dyskinesia. Trends Neurosci. 30, 236–243. 
Chaudhuri, K.R., Healy, D.G., Schapira, A.H. V, and National 
Institute for Clinical Excellence (2006). Non-motor symptoms of 
Parkinson’s disease: diagnosis and management. Lancet. Neurol. 
5, 235–245. 
Chen, J.-Z., Wang, S., Tang, R., Yang, Q.-S., Zhao, E., Chao, Y., 
Ying, K., Xie, Y., and Mao, Y.-M. (2002). Cloning and 
identification of a cDNA that encodes a novel human protein with 
thrombospondin type I repeat domain, hPWTSR. Mol. Biol. Rep. 
29, 287–292. 
Chen, P.-H., Chen, X., Lin, Z., Fang, D., and He, X. (2013). The 
structural basis of R-spondin recognition by LGR5 and RNF43. 
Genes Dev. 27, 1345–1350. 
Chi, C.L., Martinez, S., Wurst, W., and Martin, G.R. (2003). The 
isthmic organizer signal FGF8 is required for cell survival in the 
prospective midbrain and cerebellum. Development 130, 2633–
2644. 
Chung, C.Y., Seo, H., Sonntag, K.C., Brooks, A., Lin, L., and 
Isacson, O. (2005). Cell type-specific gene expression of midbrain 
dopaminergic neurons reveals molecules involved in their 
vulnerability and protection. Hum. Mol. Genet. 14, 1709–1725. 
Chung, S., Leung, A., Han, B.-S., Chang, M.-Y., Moon, J.-I., Kim, 
C.-H., Hong, S., Pruszak, J., Isacson, O., and Kim, K.-S. (2009). 
Wnt1-lmx1a forms a novel autoregulatory loop and controls 
midbrain dopaminergic differentiation synergistically with the 
SHH-FoxA2 pathway. Cell Stem Cell 5, 646–658. 
Ciruna, B., Jenny, A., Lee, D., Mlodzik, M., and Schier, A.F. 
(2006). Planar cell polarity signalling couples cell division and 
morphogenesis during neurulation. Nature 439, 220–224. 
Clevers, H., Rafelski, S., Elowitz, M., and Lein, E. (2017). What Is 
Your Conceptual Definition of “Cell Type” in the Context of a 
Mature Organism? Cell Syst. 4, 255–259. 
Cruciat, C.-M.M., and Niehrs, C. (2012). Secreted and 
Transmembrane Wnt Inhibitors and Activators. Cold Spring Harb. 
Perspect. Biol. 5, 1–26. 
Curtin, J.A., Quint, E., Tsipouri, V., Arkell, R.M., Cattanach, B., 
Copp, A.J., Henderson, D.J., Spurr, N., Stanier, P., Fisher, E.M., et 
al. (2003). Mutation of Celsr1 disrupts planar polarity of inner ear 
hair cells and causes severe neural tube defects in the mouse. Curr. 
Biol. 13, 1129–1133. 
Damier, P., Hirsch, E.C., Agid, Y., and Graybiel, A.M. (1999). 
The substantia nigra of the human brain. I. Nigrosomes and the 
nigral matrix, a compartmental organization based on calbindin 
D(28K) immunohistochemistry. Brain 122 ( Pt 8, 1421–1436. 
Danielian, P.S., and McMahon, A.P. (1996). Engrailed-1 as a 
target of the Wnt-1 signalling pathway in vertebrate midbrain 
development. Nature 383, 332–334. 
De, A. (2011). Wnt/Ca2+ signaling pathway: a brief overview. 
Acta Biochim. Biophys. Sin. (Shanghai). 43, 745–756. 
Ellisor, D., Rieser, C., Voelcker, B., Machan, J.T., and Zervas, M. 
(2012). Genetic dissection of midbrain dopamine neuron 
development in vivo. Dev. Biol. 372, 249–262. 
Endo, M., and Minami, Y. (2017). Diverse roles for the ror-family 
receptor tyrosine kinases in neurons and glial cells during 
development and repair of the nervous system. Dev. Dyn. 1–9. 
Endo, M., Doi, R., Nishita, M., and Minami, Y. (2012). Ror family 
receptor tyrosine kinases regulate the maintenance of neural 
progenitor cells in the developing neocortex. J. Cell Sci. 125, 
2017–2029. 
Fahn, S. (2003). Description of Parkinson’s disease as a clinical 
syndrome. Ann. N. Y. Acad. Sci. 991, 1–14. 
Fenstermaker, A.G., Prasad, A.A., Bechara, A., Adolfs, Y., Tissir, 
F., Goffinet, A., Zou, Y., and Pasterkamp, R.J. (2010). Wnt/planar 
cell polarity signaling controls the anterior-posterior organization 
of monoaminergic axons in the brainstem. J. Neurosci. 30, 16053–
16064. 
Fernando, C. V, Kele, J., Bye, C.R., Niclis, J.C., Alsanie, W., 
Blakely, B.D., Stenman, J., Turner, B.J., and Parish, C.L. (2014). 
Diverse roles for Wnt7a in ventral midbrain neurogenesis and 
dopaminergic axon morphogenesis. Stem Cells Dev. 23, 1991–
2003. 
Ferri, A.L.M., Lin, W., Mavromatakis, Y.E., Wang, J.C., Sasaki, 
H., Whitsett, J. a, and Ang, S.-L. (2007). Foxa1 and Foxa2 regulate 
multiple phases of midbrain dopaminergic neuron development in 
a dosage-dependent manner. Development 134, 2761–2769. 
  45 
Fishell, G., and Heintz, N. (2013). The neuron identity problem: 
Form meets function. Neuron 80, 602–612. 
Fougerousse, F., Bullen, P., Herasse, M., Lindsay, S., Richard, I., 
Wilson, D., Suel, L., Durand, M., Robson, S., Abitbol, M., et al. 
(2000). Human-mouse differences in the embryonic expression 
patterns of developmental control genes and disease genes. Hum. 
Mol. Genet. 9, 165–173. 
Fu, Y., Yuan, Y., Halliday, G., Rusznák, Z., Watson, C., and 
Paxinos, G. (2012). A cytoarchitectonic and chemoarchitectonic 
analysis of the dopamine cell groups in the substantia nigra, ventral 
tegmental area, and retrorubral field in the mouse. Brain Struct. 
Funct. 217, 591–612. 
Galli, S., Lopes, D.M., Ammari, R., Kopra, J., Millar, S.E., Gibb, 
A., and Salinas, P.C. (2014). Deficient Wnt signalling triggers 
striatal synaptic degeneration and impaired motor behaviour in 
adult mice. Nat Commun 5, 4992. 
Gao, B. (2012). Wnt regulation of planar cell polarity (PCP). Curr. 
Top. Dev. Biol. 101, 263–295. 
Gao, B., Song, H., Bishop, K., Elliot, G., Garrett, L., English, M. a, 
Andre, P., Robinson, J., Sood, R., Minami, Y., et al. (2011). Wnt 
signaling gradients establish planar cell polarity by inducing 
Vangl2 phosphorylation through Ror2. Dev. Cell 20, 163–176. 
Glinka, A., Dolde, C., Kirsch, N., Huang, Y.-L., Kazanskaya, O., 
Ingelfinger, D., Boutros, M., Cruciat, C.-M., and Niehrs, C. 
(2011). LGR4 and LGR5 are R-spondin receptors mediating 
Wnt/β-catenin and Wnt/PCP signalling. EMBO Rep. 12, 1055–
1061. 
Goetz, C.G. (2011). The History of Parkinson’s Disease: Early 
Clinical Descriptions and Neurological Therapies. Cold Spring 
Harb. Perspect. Med. 1, a008862–a008862. 
Golonzhka, O., Nord, A., Tang, P.L.F., Lindtner, S., Ypsilanti, 
A.R., Ferretti, E., Visel, A., Selleri, L., and Rubenstein, J.L.R. 
(2015). Pbx Regulates Patterning of the Cerebral Cortex in 
Progenitors and Postmitotic Neurons. Neuron 88, 1192–1207. 
Grebbin, B.M., Hau, A.-C., Groß, A., Anders-Maurer, M., 
Schramm, J., Koss, M., Wille, C., Mittelbronn, M., Selleri, L., and 
Schulte, D. (2016). Pbx1 is required for adult subventricular zone 
neurogenesis. Development 143, 2281–2291. 
Greene, J.G., Dingledine, R., and Greenamyre, J.T. (2005). Gene 
expression profiling of rat midbrain dopamine neurons: 
implications for selective vulnerability in parkinsonism. Neurobiol. 
Dis. 18, 19–31. 
Grimm, J., Mueller, A., Hefti, F., and Rosenthal, A. (2004). 
Molecular basis for catecholaminergic neuron diversity. Proc. Natl. 
Acad. Sci. U. S. A. 101, 13891–13896. 
Grün, D., and van Oudenaarden, A. (2015). Design and Analysis 
of Single-Cell Sequencing Experiments. Cell 163, 799–810. 
Gubb, D., and García-Bellido, A. (1982). A genetic analysis of the 
determination of cuticular polarity during development in 
Drosophila melanogaster. J. Embryol. Exp. Morphol. 68, 37–57. 
Guo, N., Hawkins, C., and Nathans, J. (2004). Frizzled6 controls 
hair patterning in mice. Proc. Natl. Acad. Sci. U. S. A. 101, 9277–
9281. 
Hao, H.-X., Xie, Y., Zhang, Y., Charlat, O., Oster, E., Avello, M., 
Lei, H., Mickanin, C., Liu, D., Ruffner, H., et al. (2012). ZNRF3 
promotes Wnt receptor turnover in an R-spondin-sensitive manner. 
Nature 485, 195–200. 
Hassler, J. (1938). No TitZur pathologie der paralysis agitans und 
des postencephalitschen Parkinsonismusle. J. Psychol. Neurol. 48, 
387–476. 
Hegarty, S. V, Sullivan, A.M., and O’Keeffe, G.W. (2013). 
Midbrain dopaminergic neurons: a review of the molecular 
circuitry that regulates their development. Dev. Biol. 379, 123–
138. 
Heisenberg, C.P., Tada, M., Rauch, G.J., Saúde, L., Concha, M.L., 
Geisler, R., Stemple, D.L., Smith, J.C., and Wilson, S.W. (2000). 
Silberblick/Wnt11 mediates convergent extension movements 
during zebrafish gastrulation. Nature 405, 76–81. 
Ho, H.-Y.H., Susman, M.W., Bikoff, J.B., Ryu, Y.K., Jonas, A.M., 
Hu, L., Kuruvilla, R., and Greenberg, M.E. (2012). Wnt5a-Ror-
Dishevelled signaling constitutes a core developmental pathway 
that controls tissue morphogenesis. Proc. Natl. Acad. Sci. U. S. A. 
109, 4044–4051. 
Hoekstra, E.J., von Oerthel, L., van der Heide, L.P., 
Kouwenhoven, W.M., Veenvliet, J. V., Wever, I., Jin, Y.-R., 
Yoon, J.K., van der Linden, A.J. a., Holstege, F.C.P., et al. (2013). 
Lmx1a Encodes a Rostral Set of Mesodiencephalic Dopaminergic 
Neurons Marked by the Wnt/B-Catenin Signaling Activator R-
spondin 2. PLoS One 8, e74049. 
Hood, S., and Amir, S. (2017). Neurodegeneration and the 
Circadian Clock. Front. Aging Neurosci. 9, 170. 
Hook, P.W., McClymont, S.A.H., Canoon, G.H., Law, W.D., 
Goff, L.A., McCallion, A.S., Cannon, G.H., Law, W.D., Goff, 
L.A., and McCallion, A.S. (2017). Temporal and spatial variation 
among single dopaminergic neuron transcriptomes informs cellular 
phenotype diversity and Parkinson’s Disease gene prioritization. 
BioArchives. 
Hua, Z.L., Chang, H., Wang, Y., Smallwood, P.M., and Nathans, 
J. (2014). Partial interchangeability of Fz3 and Fz6 in tissue 
polarity signaling for epithelial orientation and axon growth and 
guidance. Development 141, 3944–3954. 
Huot, P. (2015). L-DOPA-induced dyskinesia, is striatal dopamine 
depletion a requisite? J. Neurol. Sci. 351, 9–12. 
Inestrosa, N.C., and Arenas, E. (2010). Emerging roles of Wnts in 
the adult nervous system. Nat. Rev. Neurosci. 11, 77–86. 
Islam, S., Kjällquist, U., Moliner, A., Zajac, P., Fan, J.B., 
Lönnerberg, P., and Linnarsson, S. (2011). Characterization of the 
single-cell transcriptional landscape by highly multiplex RNA-seq. 
Genome Res. 21, 1160–1167. 
Islam, S., Kjällquist, U., Moliner, A., Zajac, P., Fan, J.-B., 
Lönnerberg, P., and Linnarsson, S. (2012). Highly multiplexed and 
strand-specific single-cell RNA 5’ end sequencing. Nat. Protoc. 7, 
813–828. 
Islam, S., Zeisel, A., Joost, S., La Manno, G., Zajac, P., Kasper, 
M., Lönnerberg, P., and Linnarsson, S. (2014). Quantitative single-
cell RNA-seq with unique molecular identifiers. Nat. Methods 11, 
163–166. 
Janda, C.Y., Waghray, D., Levin, A.M., Thomas, C., and Garcia, 
K.C. (2012). Structural basis of Wnt recognition by Frizzled. 
Science 337, 59–64. 
Javoy-Agid, F., and Agid, Y. (1980). Is the mesocortical 
dopaminergic system involved in Parkinson disease? Neurology 
30, 1326–1330. 
Joksimovic, M., Yun, B. a, Kittappa, R., Anderegg, A.M., Chang, 
W.W., Taketo, M.M., McKay, R.D.G., and Awatramani, R.B. 
(2009). Wnt antagonism of Shh facilitates midbrain floor plate 
neurogenesis. Nat. Neurosci. 12, 125–131. 
Kalia, L. V., and Lang, A.E. (2015). Parkinson’s disease. Lancet 
386, 896–912. 
Kazanskaya, O., Glinka, A., del Barco Barrantes, I., Stannek, P., 
Niehrs, C., and Wu, W. (2004). R-Spondin2 is a secreted activator 
 46 
of Wnt/beta-catenin signaling and is required for Xenopus 
myogenesis. Dev. Cell 7, 525–534. 
Ke, J., Xu, H.E., and Williams, B.O. (2013). Lipid modification in 
Wnt structure and function. Curr. Opin. Lipidol. 24, 129–133. 
Kee, N., Volakakis, N., Kirkeby, A., Dahl, L., Storvall, H., 
Nolbrant, S., Lahti, L., Björklund, Å.K., Gillberg, L., Joodmardi, 
E., et al. (2017). Single-Cell Analysis Reveals a Close Relationship 
between Differentiating Dopamine and Subthalamic Nucleus 
Neuronal Lineages. Cell Stem Cell 20, 29–40. 
Kefalopoulou, Z., Politis, M., Piccini, P., Mencacci, N., Bhatia, K., 
Jahanshahi, M., Widner, H., Rehncrona, S., Brundin, P., 
Björklund, A., et al. (2014). Long-term clinical outcome of fetal 
cell transplantation for Parkinson disease: two case reports. JAMA 
Neurol. 71, 83–87. 
Kele, J., Simplicio, N., Ferri, A.L.M., Mira, H., Guillemot, F., 
Arenas, E., and Ang, S.-L. (2006). Neurogenin 2 is required for the 
development of ventral midbrain dopaminergic neurons. 
Development 133, 495–505. 
Kele, J., Andersson, E.R., Villaescusa, J.C., Cajanek, L., Parish, 
C.L., Bonilla, S., Toledo, E.M., Bryja, V., Rubin, J.S., Shimono, 
A., et al. (2012). SFRP1 and SFRP2 dose-dependently regulate 
midbrain dopamine neuron development in vivo and in embryonic 
stem cells. Stem Cells 30, 865–875. 
Kibar, Z., Capra, V., and Gros, P. (2007). Toward understanding 
the genetic basis of neural tube defects. Clin. Genet. 71, 295–310. 
Kibar, Z., Salem, S., Bosoi, C.M., Pauwels, E., De Marco, P., 
Merello, E., Bassuk,  a G., Capra, V., and Gros, P. (2011). 
Contribution of VANGL2 mutations to isolated neural tube 
defects. Clin. Genet. 80, 76–82. 
Kim, K., Wagle, M., Tran, K., Zhan, X., Dixon, M.A., Liu, S., 
Gros, D., Korver, W., Yonkovich, S., Tomasevic, N., et al. (2008). 
R-Spondin family members regulate the Wnt pathway by a 
common mechanism. Mol. Biol. Cell 19, 2588–2596. 
Kim, K.-A., Kakitani, M., Zhao, J., Oshima, T., Tang, T., Binnerts, 
M., Liu, Y., Boyle, B., Park, E., Emtage, P., et al. (2005). 
Mitogenic influence of human R-spondin1 on the intestinal 
epithelium. Science 309, 1256–1259. 
Kimiwada, T., Sakurai, M., Ohashi, H., Aoki, S., Tominaga, T., 
and Wada, K. (2009). Clock genes regulate neurogenic 
transcription factors, including NeuroD1, and the neuronal 
differentiation of adult neural stem/progenitor cells. Neurochem. 
Int. 54, 277–285. 
Kirkeby, A., Grealish, S., Wolf, D.A., Nelander, J., Wood, J., 
Lundblad, M., Lindvall, O., and Parmar, M. (2012). Generation of 
regionally specified neural progenitors and functional neurons 
from human embryonic stem cells under defined conditions. Cell 
Rep. 1, 703–714. 
Kirkeby, A., Parmar, M., and Barker, R.A. (2017a). Strategies for 
bringing stem cell-derived dopamine neurons to the clinic: A 
European approach (STEM-PD) (Elsevier B.V.). 
Kirkeby, A., Nolbrant, S., Tiklova, K., Heuer, A., Kee, N., 
Cardoso, T., Ottosson, D.R., Lelos, M.J., Rifes, P., Dunnett, S.B., 
et al. (2017b). Predictive Markers Guide Differentiation to 
Improve Graft Outcome in Clinical Translation of hESC-Based 
Therapy for Parkinson’s Disease. Cell Stem Cell 20, 135–148. 
Kivioja, T., Vähärautio, A., Karlsson, K., Bonke, M., Enge, M., 
Linnarsson, S., and Taipale, J. (2011). Counting absolute numbers 
of molecules using unique molecular identifiers. Nat. Methods 9, 
72–74. 
Klingelhoefer, L., and Reichmann, H. (2015). Pathogenesis of 
Parkinson disease--the gut-brain axis and environmental factors. 
Nat. Rev. Neurol. 11, 625–636. 
Kolodziejczyk, A.A., Kim, J.K., Svensson, V., Marioni, J.C., and 
Teichmann, S.A. (2015). The Technology and Biology of Single-
Cell RNA Sequencing. Mol. Cell 58, 610–620. 
Komiya, Y., and Habas, R. (2008). Wnt signal transduction 
pathways. Organogenesis 4, 68–75. 
Kondratov, R. V, Kondratova, A.A., Gorbacheva, V.Y., 
Vykhovanets, O. V, and Antoch, M.P. (2006). Early aging and 
age-related pathologies in mice deficient in BMAL1, the core 
componentof the circadian clock. Genes Dev. 20, 1868–1873. 
Koo, B.-K., Spit, M., Jordens, I., Low, T.Y., Stange, D.E., van de 
Wetering, M., van Es, J.H., Mohammed, S., Heck, A.J.R., 
Maurice, M.M., et al. (2012). Tumour suppressor RNF43 is a 
stem-cell E3 ligase that induces endocytosis of Wnt receptors. 
Nature 488, 665–669. 
Krack, P., Martinez-Fernandez, R., del Alamo, M., and Obeso, 
J.A. (2017). Current applications and limitations of surgical 
treatments for movement disorders. Mov. Disord. 32, 36–52. 
Kriks, S., Shim, J.-W., Piao, J., Ganat, Y.M., Wakeman, D.R., Xie, 
Z., Carrillo-Reid, L., Auyeung, G., Antonacci, C., Buch, A., et al. 
(2011). Dopamine neurons derived from human ES cells 
efficiently engraft in animal models of Parkinson’s disease. Nature 
480, 547–551. 
Langston, J.W., Ballard, P., Tetrud, J.W., and Irwin, I. (1983). 
Chronic Parkinsonism in humans due to a product of meperidine-
analog synthesis. Science 219, 979–980. 
de Lau, L.M.L., and Breteler, M.M.B. (2006). Epidemiology of 
Parkinson’s disease. Lancet. Neurol. 5, 525–535. 
de Lau, W., Barker, N., Low, T.Y., Koo, B.-K., Li, V.S.W., 
Teunissen, H., Kujala, P., Haegebarth, A., Peters, P.J., van de 
Wetering, M., et al. (2011). Lgr5 homologues associate with Wnt 
receptors and mediate R-spondin signalling. Nature 476, 293–297. 
Lei, Y.-P., Zhang, T., Li, H., Wu, B.-L., Jin, L., and Wang, H.-Y. 
(2010). VANGL2 mutations in human cranial neural-tube defects. 
N. Engl. J. Med. 362, 2232–2235. 
Li, S.J., Yen, T.Y., Endo, Y., Klauzinska, M., Baljinnyam, B., 
Macher, B., Callahan, R., and Rubin, J.S. (2009). Loss-of-function 
point mutations and two-furin domain derivatives provide insights 
about R-spondin2 structure and function. Cell. Signal. 21, 916–
925. 
Lindvall, O., and Kokaia, Z. (2009). Prospects of stem cell therapy 
for replacing dopamine neurons in Parkinson’s disease. Trends 
Pharmacol. Sci. 30, 260–267. 
Linnarsson, S., and Teichmann, S.A. (2016). Single-cell genomics: 
coming of age. Genome Biol. 17, 97. 
Liu, Y., Rubin, B., Bodine, P.V.N., and Billiard, J. (2008). Wnt5a 
induces homodimerization and activation of Ror2 receptor tyrosine 
kinase. J. Cell. Biochem. 105, 497–502. 
Longobardi, E., Penkov, D., Mateos, D., De Florian, G., Torres, 
M., and Blasi, F. (2014). Biochemistry of the tale transcription 
factors PREP, MEIS, and PBX in vertebrates. Dev. Dyn. 243, 59–
75. 
Lu, W., Yamamoto, V., Ortega, B., and Baltimore, D. (2004). 
Mammalian Ryk is a Wnt coreceptor required for stimulation of 
neurite outgrowth. Cell 119, 97–108. 
Luo, L., Callaway, E.M., and Svoboda, K. (2008). Genetic 
Dissection of Neural Circuits. Neuron 57, 634–660. 
Van der Maaten, L., Hinton, G., der Maaten, L., and Hinton, G. 
(2008). Visualizing Data using t-SNE. In Journal of Machine 
Learning Research, pp. 2579–2605. 
  47 
MacDonald, B.T., and He, X. (2012). Frizzled and LRP5/6 
receptors for Wnt/β-catenin signaling. Cold Spring Harb. Perspect. 
Biol. 4, a007880–a007880. 
MacDonald, B.T., Tamai, K., and He, X. (2009). Wnt/beta-catenin 
signaling: components, mechanisms, and diseases. Dev. Cell 17, 
9–26. 
Malik, A., Kondratov, R. V, Jamasbi, R.J., and Geusz, M.E. 
(2015). Circadian Clock Genes Are Essential for Normal Adult 
Neurogenesis, Differentiation, and Fate Determination. PLoS One 
10, e0139655. 
Malinauskas, T., and Jones, E.Y. (2014). Extracellular modulators 
of Wnt signalling. Curr. Opin. Struct. Biol. 29C, 77–84. 
La Manno, G., Gyllborg, D., Codeluppi, S., Nishimura, K., Salto, 
C., Zeisel, A., Borm, L.E., Stott, S.R.W., Toledo, E.M., 
Villaescusa, J.C., et al. (2016). Molecular Diversity of Midbrain 
Development in Mouse, Human, and Stem Cells. Cell 167, 566–
580.e19. 
Marques, S., Zeisel, A., Codeluppi, S., van Bruggen, D., 
Mendanha Falcao, A., Xiao, L., Li, H., Haring, M., Hochgerner, 
H., Romanov, R.A., et al. (2016). Oligodendrocyte heterogeneity 
in the mouse juvenile and adult central nervous system. Science 
352, 1326–1329. 
Martinez, S., Scerbo, P., Giordano, M., Daulat, A.M., Lhoumeau, 
A.-C.C., Thomé, V., Kodjabachian, L., and Borg, J.-P.P. (2015). 
The PTK7 and ROR2 protein receptors interact in the vertebrate 
WNT/Planar cell polarity (PCP) pathway. J. Biol. Chem. 290, 
30562–30572. 
Marzo, A., Galli, S., Lopes, D., McLeod, F., Podpolny, M., 
Segovia-Roldan, M., Ciani, L., Purro, S., Cacucci, F., Gibb, A., et 
al. (2016). Reversal of Synapse Degeneration by Restoring Wnt 
Signaling in the Adult Hippocampus. Curr. Biol. 26, 2551–2561. 
Masland, R.H. (2004). Neuronal cell types. Curr. Biol. 14, R497–
R500. 
McMahon, A.P., and Bradley, A. (1990). The Wnt-1 (int-1) proto-
oncogene is required for development of a large region of the 
mouse brain. Cell 62, 1073–1085. 
McRitchie, D. a, Hardman, C.D., and Halliday, G.M. (1996). 
Cytoarchitectural distribution of calcium binding proteins in 
midbrain dopaminergic regions of rats and humans. J. Comp. 
Neurol. 364, 121–150. 
Menet, J.S., Pescatore, S., and Rosbash, M. (2014). 
CLOCK:BMAL1 is a pioneer-like transcription factor. Genes Dev. 
28, 8–13. 
Mikels, A.J., and Nusse, R. (2006). Purified Wnt5a protein 
activates or inhibits beta-catenin-TCF signaling depending on 
receptor context. PLoS Biol. 4, e115. 
Miocinovic, S., Somayajula, S., Chitnis, S., and Vitek, J.L. (2013). 
History, Applications, and Mechanisms of Deep Brain 
Stimulation. JAMA Neurol. 70, 163. 
Montcouquiol, M., Rachel, R. a, Lanford, P.J., Copeland, N.G., 
Jenkins, N. a, and Kelley, M.W. (2003). Identification of Vangl2 
and Scrb1 as planar polarity genes in mammals. Nature 423, 173–
177. 
Musiek, E.S., and Holtzman, D.M. (2016). Mechanisms linking 
circadian clocks, sleep, and neurodegeneration. Science 354, 
1004–1008. 
Nalls, M. a, Pankratz, N., Lill, C.M., Do, C.B., Hernandez, D.G., 
Saad, M., DeStefano, A.L., Kara, E., Bras, J., Sharma, M., et al. 
(2014). Large-scale meta-analysis of genome-wide association 
data identifies six new risk loci for Parkinson’s disease. Nat. 
Genet. 56, 1–7. 
Nam, J.-S., Turcotte, T.J., Smith, P.F., Choi, S., and Yoon, J.K. 
(2006). Mouse cristin/R-spondin family proteins are novel ligands 
for the Frizzled 8 and LRP6 receptors and activate beta-catenin-
dependent gene expression. J. Biol. Chem. 281, 13247–13257. 
Nelander, J., Hebsgaard, J.B., and Parmar, M. (2009). 
Organization of the human embryonic ventral mesencephalon. 
Gene Expr. Patterns 9, 555–561. 
Nelson, S.B., Sugino, K., and Hempel, C.M. (2016). The problem 
of neuronal cell types: a physiological genomics approach. Trends 
Neurosci. 29, 339–345. 
Ni, N., Hu, Y., Ren, H., Luo, C., Li, P., Wan, J.-B., and Su, H. 
(2013). Self-assembling Peptide nanofiber scaffolds enhance 
dopaminergic differentiation of mouse pluripotent stem cells in 3-
dimensional culture. PLoS One 8, e84504. 
Niehrs, C. (2012). The complex world of WNT receptor signalling. 
Nat. Rev. Mol. Cell Biol. 13, 767–779. 
Nikolopoulou, E., Galea, G.L., Rolo, A., Greene, N.D.E., and 
Copp, A.J. (2017). Neural tube closure: cellular, molecular and 
biomechanical mechanisms. Development 144, 552–566. 
Nishita, M., Itsukushima, S., Nomachi, A., Endo, M., Wang, Z., 
Inaba, D., Qiao, S., Takada, S., Kikuchi, A., and Minami, Y. 
(2010). Ror2/Frizzled complex mediates Wnt5a-induced AP-1 
activation by regulating Dishevelled polymerization. Mol. Cell. 
Biol. 30, 3610–3619. 
Nusse, R., and Clevers, H. (2017). Wnt/β-Catenin Signaling, 
Disease, and Emerging Therapeutic Modalities. Cell 169, 985–
999. 
Nusse, R., and Varmus, H. (1982). Many tumors induced by 
mouse mammary tumor virus contain a provirus integrated in the 
same region of the host chromosome. Cell 31, 99–109. 
Nusse, R., and Varmus, H. (2012). Three decades of Wnts: a 
personal perspective on how a scientific field developed. EMBO J. 
31, 2670–2684. 
Nusse, R., and Varmus, H.E. (1992). Wnt genes. Cell 69, 1073–
1087. 
Nusse, R., Brown, A., Papkoff, J., Scambler, P., Shackleford, G., 
McMahon, A., Moon, R., and Varmus, H. (1991). A new 
nomenclature for int-1 and related genes: the Wnt gene family. 
Cell 64, 231. 
Ohkawara, B., Glinka, A., and Niehrs, C. (2011). Rspo3 binds 
syndecan 4 and induces Wnt/PCP signaling via clathrin-mediated 
endocytosis to promote morphogenesis. Dev. Cell 20, 303–314. 
Oishi, I., Takeuchi, S., Hashimoto, R., Nagabukuro, A., Ueda, T., 
Liu, Z.J., Hatta, T., Akira, S., Matsuda, Y., Yamamura, H., et al. 
(1999). Spatio-temporally regulated expression of receptor tyrosine 
kinases, mRor1, mRor2, during mouse development: implications 
in development and function of the nervous system. Genes Cells 4, 
41–56. 
Ono, Y., Nakatani, T., Sakamoto, Y., Mizuhara, E., Minaki, Y., 
Kumai, M., Hamaguchi, A., Nishimura, M., Inoue, Y., Hayashi, 
H., et al. (2007). Differences in neurogenic potential in floor plate 
cells along an anteroposterior location: midbrain dopaminergic 
neurons originate from mesencephalic floor plate cells. 
Development 134, 3213–3225. 
Ono, Y., Nakatani, T., Minaki, Y., and Kumai, M. (2010). The 
basic helix-loop-helix transcription factor Nato3 controls 
neurogenic activity in mesencephalic floor plate cells. 
Development 137, 1897–1906. 
Ossipova, O., Kim, K., and Sokol, S.Y. (2015). Planar polarization 
of Vangl2 in the vertebrate neural plate is controlled by Wnt and 
Myosin II signaling. Biol. Open 4, 722–730. 
 48 
Paganoni, S., Bernstein, J., and Ferreira, A. (2010). Ror1-Ror2 
complexes modulate synapse formation in hippocampal neurons. 
Neuroscience 165, 1261–1274. 
Panman, L., Papathanou, M., Laguna, A., Oosterveen, T., 
Volakakis, N., Acampora, D., Kurtsdotter, I., Yoshitake, T., Kehr, 
J., Joodmardi, E., et al. (2014). Sox6 and Otx2 control the 
specification of substantia nigra and ventral tegmental area 
dopamine neurons. Cell Rep. 8, 1018–1025. 
Parish, C.L., Castelo-Branco, G., Rawal, N., Tonnesen, J., 
Sorensen, A.T., Salto, C., Kokaia, M., Lindvall, O., and Arenas, E. 
(2008). Wnt5a-treated midbrain neural stem cells improve 
dopamine cell replacement therapy in parkinsonian mice. J. Clin. 
Invest. 118, 149–160. 
Park, A., and Stacy, M. (2009). Non-motor symptoms in 
Parkinson’s disease. J. Neurol. 256, 293–298. 
Petrova, I.M., Malessy, M.J., Verhaagen, J., Fradkin, L.G., and 
Noordermeer, J.N. (2014). Wnt signaling through the Ror receptor 
in the nervous system. Mol. Neurobiol. 49, 303–315. 
Pinson, K.I., Brennan, J., Monkley, S., Avery, B.J., and Skarnes, 
W.C. (2000). An LDL-receptor-related protein mediates Wnt 
signalling in mice. Nature 407, 535–538. 
Podleschny, M., Grund, A., Berger, H., Rollwitz, E., and Borchers, 
A. (2015). A PTK7/Ror2 Co-Receptor Complex Affects Xenopus 
Neural Crest Migration. PLoS One 10, e0145169. 
Polakis, P. (2012). Wnt signaling in cancer. Cold Spring 
Harb.Perspect.Biol. 4(5). pii, a008052. 
Pollen, A. a, Nowakowski, T.J., Shuga, J., Wang, X., Leyrat, A. a, 
Lui, J.H., Li, N., Szpankowski, L., Fowler, B., Chen, P., et al. 
(2014). Low-coverage single-cell mRNA sequencing reveals 
cellular heterogeneity and activated signaling pathways in 
developing cerebral cortex. Nat. Biotechnol. 32, 1–37. 
Poulin, J., Tasic, B., Hjerling-Leffler, J., Trimarchi, J.M., and 
Awatramani, R. (2016). Disentangling neural cell diversity using 
single-cell transcriptomics. Nat. Neurosci. 19, 1131–1141. 
Poulin, J.-F.F., Zou, J., Drouin-Ouellet, J., Kim, K.-Y.Y.A., 
Cicchetti, F., and Awatramani, R.B. (2014). Defining midbrain 
dopaminergic neuron diversity by single-cell gene expression 
profiling. Cell Rep. 9, 930–943. 
Prakash, N., Brodski, C., Naserke, T., Puelles, E., Gogoi, R., Hall, 
A., Panhuysen, M., Echevarria, D., Sussel, L., Weisenhorn, 
D.M.V., et al. (2006). A Wnt1-regulated genetic network controls 
the identity and fate of midbrain-dopaminergic progenitors in vivo. 
Development 133, 89–98. 
Prakash, N., Puelles, E., Freude, K., Trümbach, D., Omodei, D., Di 
Salvio, M., Sussel, L., Ericson, J., Sander, M., Simeone, A., et al. 
(2009). Nkx6-1 controls the identity and fate of red nucleus and 
oculomotor neurons in the mouse midbrain. Development 136, 
2545–2555. 
Purro, S.A., Galli, S., and Salinas, P.C. (2014). Dysfunction of 
Wnt signaling and synaptic disassembly in neurodegenerative 
diseases. J. Mol. Cell Biol. 6, 75–80. 
Randall, R.M., Shao, Y.Y., Wang, L., and Ballock, R.T. (2012). 
Activation of Wnt Planar cell polarity (PCP) signaling promotes 
growth plate column formation in vitro. J. Orthop. Res. 30, 1906–
1914. 
Rekaik, H., Blaudin de Thé, F.-X., Prochiantz, A., Fuchs, J., and 
Joshi, R.L. (2015). Dissecting the role of Engrailed in adult 
dopaminergic neurons - Insights into Parkinson disease 
pathogenesis. FEBS Lett. 589, 3786–3794. 
Rhinn, M., Lun, K., Luz, M., Werner, M., and Brand, M. (2005). 
Positioning of the midbrain-hindbrain boundary organizer through 
global posteriorization of the neuroectoderm mediated by Wnt8 
signaling. Development 132, 1261–1272. 
Rhinn, M., Lun, K., Ahrendt, R., Geffarth, M., and Brand, M. 
(2009). Zebrafish gbx1 refines the midbrain-hindbrain boundary 
border and mediates the Wnt8 posteriorization signal. Neural Dev. 
4, 12. 
Ribeiro, D., Ellwanger, K., Glagow, D., Theofilopoulos, S., 
Corsini, N.S., Martin-Villalba, A., Niehrs, C., and Arenas, E. 
(2011). Dkk1 regulates ventral midbrain dopaminergic 
differentiation and morphogenesis. PLoS One 6, e15786. 
Rijsewijk, F., Schuermann, M., Wagenaar, E., Parren, P., Weigel, 
D., and Nusse, R. (1987). The Drosophila homology of the mouse 
mammary oncogene int-1 is identical to the segment polarity gene 
wingless. Cell 50, 649–657. 
Rivetti di Val Cervo, P., Romanov, R.A., Spigolon, G., Masini, D., 
Martín-Montañez, E., Toledo, E.M., La Manno, G., Feyder, M., 
Pifl, C., Ng, Y.-H., et al. (2017). Induction of functional dopamine 
neurons from human astrocytes in vitro and mouse astrocytes in a 
Parkinson’s disease model. Nat. Biotechnol. 35, 444–452. 
Roeper, J. (2013). Dissecting the diversity of midbrain dopamine 
neurons. Trends Neurosci. 36, 336–342. 
Salašová, A., Yokota, C., Potěšil, D., Zdráhal, Z., Bryja, V., and 
Arenas, E. (2017). A proteomic analysis of LRRK2 binding 
partners reveals interactions with multiple signaling components of 
the WNT/PCP pathway. Mol. Neurodegener. 12, 54. 
Schapira, A.H. V, Chaudhuri, K.R., and Jenner, P. (2017). Non-
motor features of Parkinson disease. Nat. Rev. Neurosci. 
Schulte, D., and Frank, D. (2014). TALE transcription factors 
during early development of the vertebrate brain and eye. Dev. 
Dyn. 243, 99–116. 
Schulte, G., Bryja, V., Rawal, N., Castelo-Branco, G., Sousa, 
K.M., and Arenas, E. (2005). Purified Wnt-5a increases 
differentiation of midbrain dopaminergic cells and dishevelled 
phosphorylation. J. Neurochem. 92, 1550–1553. 
Seifert, J.R.K., and Mlodzik, M. (2007). Frizzled/PCP signalling: a 
conserved mechanism regulating cell polarity and directed 
motility. Nat. Rev. Genet. 8, 126–138. 
Serafino, A., Sferrazza, G., Colini Baldeschi, A., Nicotera, G., 
Andreola, F., Pittaluga, E., and Pierimarchi, P. (2016). Developing 
drugs that target the Wnt pathway: recent approaches in cancer and 
neurodegenerative diseases. Expert Opin. Drug Discov. 12, 
17460441.2017.1271321. 
Sgadò, P., Ferretti, E., Grbec, D., Bozzi, Y., and Simon, H.H. 
(2012). The atypical homeoprotein Pbx1a participates in the 
axonal pathfinding of mesencephalic dopaminergic neurons. 
Neural Dev. 7, 24. 
Shapiro, E., Biezuner, T., and Linnarsson, S. (2013). Single-cell 
sequencing-based technologies will revolutionize whole-organism 
science. Nat. Rev. Genet. 14, 618–630. 
Shults, C.W. (2006). Lewy bodies. Proc. Natl. Acad. Sci. U. S. A. 
103, 1661–1668. 
Singh, J., and Mlodzik, M. (2012). Planar cell polarity signaling: 
Coordination of cellular orientation across tissues. Wiley 
Interdiscip. Rev. Dev. Biol. 1, 479–499. 
Smidt, M.P., Asbreuk, C.H., Cox, J.J., Chen, H., Johnson, R.L., 
and Burbach, J.P. (2000). A second independent pathway for 
development of mesencephalic dopaminergic neurons requires 
Lmx1b. Nat. Neurosci. 3, 337–341. 
Smits, S.M., Burbach, J.P.H., and Smidt, M.P. (2006). 
Developmental origin and fate of meso-diencephalic dopamine 
  49 
neurons. Prog. Neurobiol. 78, 1–16. 
Smits, S.M., von Oerthel, L., Hoekstra, E.J., Burbach, J.P.H., and 
Smidt, M.P. (2013). Molecular marker differences relate to 
developmental position and subsets of mesodiencephalic 
dopaminergic neurons. PLoS One 8, e76037. 
Song, H., Hu, J., Chen, W., Elliott, G., Andre, P., Gao, B., and 
Yang, Y. (2010). Planar cell polarity breaks bilateral symmetry by 
controlling ciliary positioning. Nature 466, 378–382. 
Sousa, K.M., Villaescusa, J.C., Cajanek, L., Ondr, J.K., Castelo-
Branco, G., Hofstra, W., Bryja, V., Palmberg, C., Bergman, T., 
Wainwright, B., et al. (2010). Wnt2 regulates progenitor 
proliferation in the developing ventral midbrain. J. Biol. Chem. 
285, 7246–7253. 
Spillantini, M.G., Crowther, R.A., Jakes, R., Hasegawa, M., and 
Goedert, M. (1998). alpha-Synuclein in filamentous inclusions of 
Lewy bodies from Parkinson’s disease and dementia with lewy 
bodies. Proc. Natl. Acad. Sci. U. S. A. 95, 6469–6473. 
Stegle, O., Teichmann, S.A., and Marioni, J.C. (2015). 
Computational and analytical challenges in single-cell 
transcriptomics. Nat. Rev. Genet. 16, 133–145. 
Stevens, J.D., Roalson, E.H., and Skinner, M.K. (2008). 
Phylogenetic and expression analysis of the basic helix-loop-helix 
transcription factor gene family: genomic approach to cellular 
differentiation. Differentiation. 76, 1006–1022. 
Stricker, S., Rauschenberger, V., and Schambony, A. (2017). 
ROR-Family Receptor Tyrosine Kinases (Elsevier Inc.). 
Stuebner, S., Faus-Kessler, T., Fischer, T., Wurst, W., and 
Prakash, N. (2010). Fzd3 and Fzd6 deficiency results in a severe 
midbrain morphogenesis defect. Dev. Dyn. 239, 246–260. 
Sugimura, R., and Li, L. (2010). Noncanonical Wnt signaling in 
vertebrate development, stem cells, and diseases. Birth Defects 
Res. C. Embryo Today 90, 243–256. 
Sundberg, M., and Isacson, O. (2014). Advances in stem-cell--
generated transplantation therapy for Parkinson’s disease. Expert 
Opin. Biol. Ther. 14, 437–453. 
Tada, M., and Smith, J.C. (2000). Xwnt11 is a target of Xenopus 
Brachyury: regulation of gastrulation movements via Dishevelled, 
but not through the canonical Wnt pathway. Development 127, 
2227–2238. 
Takada, S., Fujimori, S., Shinozuka, T., Takada, R., and Mii, Y. 
(2017). Differences in the secretion and transport of Wnt proteins. 
J. Biochem. 161, 1–7. 
Takeuchi, S., Takeda, K., Oishi, I., Nomi, M., Ikeya, M., Itoh, K., 
Tamura, S., Ueda, T., Hatta, T., Otani, H., et al. (2000). Mouse 
Ror2 receptor tyrosine kinase is required for the heart development 
and limb formation. Genes Cells 5, 71–78. 
Tamai, K., Semenov, M., Kato, Y., Spokony, R., Liu, C., 
Katsuyama, Y., Hess, F., Saint-Jeannet, J.P., and He, X. (2000). 
LDL-receptor-related proteins in Wnt signal transduction. Nature 
407, 530–535. 
Tawk, M., Araya, C., Lyons, D.A., Reugels, A.M., Girdler, G.C., 
Bayley, P.R., Hyde, D.R., Tada, M., and Clarke, J.D.W. (2007). A 
mirror-symmetric cell division that orchestrates neuroepithelial 
morphogenesis. Nature 446, 797–800. 
Tecuapetla, F., Patel, J.C., Xenias, H., English, D., Tadros, I., 
Shah, F., Berlin, J., Deisseroth, K., Rice, M.E., Tepper, J.M., et al. 
(2010). Glutamatergic signaling by mesolimbic dopamine neurons 
in the nucleus accumbens. J. Neurosci. 30, 7105–7110. 
Thomas, K.R., and Capecchi, M.R. (1990). Targeted disruption of 
the murine int-1 proto-oncogene resulting in severe abnormalities 
in midbrain and cerebellar development. Nature 346, 847–850. 
Thompson, L., Barraud, P., Andersson, E., Kirik, D., and 
Björklund, A. (2005). Identification of dopaminergic neurons of 
nigral and ventral tegmental area subtypes in grafts of fetal ventral 
mesencephalon based on cell morphology, protein expression, and 
efferent projections. J. Neurosci. 25, 6467–6477. 
Toledo, E.M., Colombres, M., and Inestrosa, N.C. (2008). Wnt 
signaling in neuroprotection and stem cell differentiation. Prog. 
Neurobiol. 86, 281–296. 
Toledo, E.M., Gyllborg, D., and Arenas, E. (2017). Translation of 
WNT developmental programs into stem cell replacement 
strategies for the treatment of Parkinson’s disease. Br. J. 
Pharmacol. 2014–2015. 
Torban, E., Kor, C., and Gros, P. (2004). Van Gogh-like2 
(Strabismus) and its role in planar cell polarity and convergent 
extension in vertebrates. Trends Genet. 20, 570–577. 
Trapnell, C. (2015). Defining cell types and states with single-cell 
genomics. Genome Res. 25, 1491–1498. 
Treutlein, B., Brownfield, D.G., Wu, A.R., Neff, N.F., Mantalas, 
G.L., Espinoza, F.H., Desai, T.J., Krasnow, M.A., and Quake, S.R. 
(2014). Reconstructing lineage hierarchies of the distal lung 
epithelium using single-cell RNA-seq. Nature 509, 371–375. 
Trinh, J., and Farrer, M. (2013). Advances in the genetics of 
Parkinson disease. Nat. Rev. Neurol. 9, 445–454. 
Trounson, A., and McDonald, C. (2015). Stem Cell Therapies in 
Clinical Trials: Progress and Challenges. Cell Stem Cell 17, 11–
22. 
Veenvliet, J. V, Dos Santos, M.T.M.A., Kouwenhoven, W.M., von 
Oerthel, L., Lim, J.L., van der Linden, A.J. a, Koerkamp, 
M.J.A.G., Holstege, F.C.P., and Smidt, M.P. (2013). Specification 
of dopaminergic subsets involves interplay of En1 and Pitx3. 
Development 140, 3373–3384. 
Villaescusa, J.C., Li, B., Toledo, E.M., Rivetti di Val Cervo, P., 
Yang, S., Stott, S.R., Kaiser, K., Islam, S., Gyllborg, D., Laguna-
Goya, R., et al. (2016). A PBX1 transcriptional network controls 
dopaminergic neuron development and is impaired in Parkinson’s 
disease. EMBO J. 1–16. 
Wallingford, J.B., and Harland, R.M. (2002). Neural tube closure 
requires Dishevelled-dependent convergent extension of the 
midline. Development 129, 5815–5825. 
Wang, D., Huang, B., Zhang, S., Yu, X., Wu, W., and Wang, X. 
(2013). Structural basis for R-spondin recognition by LGR4/5/6 
receptors. Genes Dev. 27, 1339–1344. 
Wang, T.-Y.Y., Bruggeman, K.F., Kauhausen, J.A., Rodriguez, 
A.L., Nisbet, D.R., and Parish, C.L. (2016). Functionalized 
composite scaffolds improve the engraftment of transplanted 
dopaminergic progenitors in a mouse model of Parkinson’s 
disease. Biomaterials 74, 89–98. 
Wansleeben, C., and Meijlink, F. (2011). The planar cell polarity 
pathway in vertebrate development. Dev. Dyn. 240, 616–626. 
Wehrli, M., Dougan, S.T., Caldwell, K., O’Keefe, L., Schwartz, S., 
Vaizel-Ohayon, D., Schejter, E., Tomlinson, A., and DiNardo, S. 
(2000). arrow encodes an LDL-receptor-related protein essential 
for Wingless signalling. Nature 407, 527–530. 
Wei, Q., Yokota, C., Semenov, M. V, Doble, B., Woodgett, J., and 
He, X. (2007). R-spondin1 is a high affinity ligand for LRP6 and 
induces LRP6 phosphorylation and beta-catenin signaling. J. Biol. 
Chem. 282, 15903–15911. 
Whitfield, A.C., Moore, B.T., and Daniels, R.N. (2014). Classics 
in chemical neuroscience: levodopa. ACS Chem. Neurosci. 5, 
 50 
1192–1197. 
Willert, K., and Nusse, R. (2012). Wnt proteins. Cold Spring Harb. 
Perspect. Biol. 4. 
Wolters, E.C., and Francot, C.M. (1998). Mental dysfunction in 
Parkinson’s disease. Parkinsonism Relat. Disord. 4, 107–112. 
Xi, J., Liu, Y., Liu, H., Chen, H., Emborg, M.E., and Zhang, S.-
C.C. (2012). Specification of midbrain dopamine neurons from 
primate pluripotent stem cells. Stem Cells 30, 1655–1663. 
Yamaguchi, T.P., Bradley,  a, McMahon,  a P., and Jones, S. 
(1999). A Wnt5a pathway underlies outgrowth of multiple 
structures in the vertebrate embryo. Development 126, 1211–1223. 
Yamamoto, S., Nishimura, O., Misaki, K., Nishita, M., Minami, 
Y., Yonemura, S., Tarui, H., and Sasaki, H. (2008). Cthrc1 
selectively activates the planar cell polarity pathway of Wnt 
signaling by stabilizing the Wnt-receptor complex. Dev. Cell 15, 
23–36. 
Yan, C.H., Levesque, M., Claxton, S., Johnson, R.L., and Ang, S.-
L. (2011). Lmx1a and lmx1b function cooperatively to regulate 
proliferation, specification, and differentiation of midbrain 
dopaminergic progenitors. J. Neurosci. 31, 12413–12425. 
Yang, Y., and Mlodzik, M. (2015). Wnt-Frizzled/Planar Cell 
Polarity Signaling: Cellular Orientation by Facing the Wind (Wnt). 
Annu. Rev. Cell Dev. Biol. 31, 623–646. 
Yang, J., Brown, A., Ellisor, D., Paul, E., Hagan, N., and Zervas, 
M. (2013a). Dynamic temporal requirement of Wnt1 in midbrain 
dopamine neuron development. Development 140, 1342–1352. 
Yang, S., Edman, L.C., Sánchez-Alcañiz, J.A., Fritz, N., Bonilla, 
S., Hecht, J., Uhlén, P., Pleasure, S.J., Villaescusa, J.C., Marín, O., 
et al. (2013b). Cxcl12/Cxcr4 signaling controls the migration and 
process orientation of A9-A10 dopaminergic neurons. 
Development 140, 4554–4564. 
Ye, W., Shimamura, K., Rubenstein, J.L., Hynes, M.A., and 
Rosenthal, A. (1998). FGF and Shh signals control dopaminergic 
and serotonergic cell fate in the anterior neural plate. Cell 93, 755–
766. 
Zebisch, M., Xu, Y., Krastev, C., MacDonald, B.T., Chen, M., 
Gilbert, R.J.C., He, X., and Jones, E.Y. (2013). Structural and 
molecular basis of ZNRF3/RNF43 transmembrane ubiquitin ligase 
inhibition by the Wnt agonist R-spondin. Nat. Commun. 4, 2787. 
Zeisel, A., Munoz-Manchado, A.B., Codeluppi, S., Lonnerberg, P., 
La Manno, G., Jureus, A., Marques, S., Munguba, H., He, L., 
Betsholtz, C., et al. (2015). Cell types in the mouse cortex and 
hippocampus revealed by single-cell RNA-seq. Science (80-. ). 
347, 1138–1142. 
Zhang, D., Yang, S., Toledo, E.M., Gyllborg, D., Saltó1, C., 
Villaescusa, J.C., and Arenas, E. (2017). Niche-derived laminin-
511 promotes midbrain dopaminergic neuron survival and 
differentiation via YAP. Sci. Signal. 
Zimmerman, Z.F., Moon, R.T., and Chien, A.J. (2012). Targeting 
Wnt pathways in disease. Cold Spring Harb. Perspect. Biol. 4. 
 
